

Subject Index

A

- Abdominal fat, genome-wide scan for, in Québec Family Study, 614
- Acetyl-CoA carboxylase, regulation of, in β -cells, 1580
- Acinar dysmorphogenesis, by PDX-1 misexpression in exocrine pancreas, 1553
- Actin, early glucose adduct formation by, in diabetes, 1666
- Activin type 2B receptor gene (*ACVR2B*), diabetes-associated mutations in French patients, 1219
- 1-Acyl-glycerol-3-phosphate acyltransferase- α , overexpression effects in adipose tissue and skeletal muscle, 233
- Adeno-associated virus, islet cell transduction with, 515
- Adenosine diphosphate (ADP), free, in insulin-secreting cells, 291
- Adenosine monophosphate (AMP)-activated protein kinase activation of in insulin-resistant rats, 1076 in type 2 diabetes, 921 HNF-4 α target, 1515
- Adenosine triphosphate (ATP)-sensitive K⁺ channels activation by insulin, in β -cells, 2192 in endocrine pancreas cell survival and differentiation, 548 nicorandil action on, 2253
- Adenovirus Av3hGKRP, for type 2 diabetes, 1813 early region 3 genes, diabetes decrease by, in NOD mice, 980 glucokinase expression by, phenotypic correction of diabetes by, in mice, 2287
- Adenylyl cyclase, activity in rat islets, 2505
- Adipocyte markers, mRNA levels, bezafibrate and, 1883
- Adipocytes differentiation of, inhibition by indinavir, 1378 fatty acid oxidation in, bezafibrate and, 1883 GLUT4 translocation by troglitazone in, rat, 2296 insulin receptor dephosphorylation in, rat, 83 lipolysis alterations in, subcellular localization of IRS family proteins and, in mice, 1455 metabolism of, nelfinavir effects on, 1425 MMP-2 and MMP-9 production by, 2080 3T3-L1 metabolism of, nelfinavir effects on, 1425 VEGF mRNA levels, troglitazone treatment effects on, 1166
- Adiponectin circulating levels in insulin resistance, in rhesus monkeys, 1126 expression of, PPAR γ ligands and, 2094 Adipose tissue. *see also* Fat AGAT- α overexpression effects in, 233 differentiation of, MMP-2 and MMP-9 effects in, 2080 gene expression regulation by insulin in, human, 1134 remodeling of, pioglitazone and, 1863
- Adiposity. *see also* Obesity HDLs in, apoA-II transgenic mice, 643 regulatory effects of leptin on, H₁-receptor disruption and, in mice, 385
- ADP (adenosine diphosphate), free, in insulin-secreting cells, 291
- Adrenal gland, sympathetic activity in, effects of hypoglycemia on, in rats, 1119
- α_1 -Adrenergic receptors, blockade, insulin secretion and glucose kinetics during exercise with, 1834
- α_2 -Adrenergic receptors, blockade, insulin secretion and glucose kinetics during exercise with, 1834
- α_{2B} -Adrenergic receptors, gene variants, and obesity, in Caucasian women, 91
- β_1 -Adrenergic receptors, diabetes effects on expression in rat hearts, 455
- β_2 -Adrenergic receptors, diabetes effects on expression in rat hearts, 455
- β_3 -Adrenergic receptors agonist AJ-9677, insulin resistance amelioration by, in KK-A^y/Ta diabetic obese mouse, 113 expression in heart, diabetes effects on, in rat, 455 gene variants, and obesity, in Caucasian women, 91
- β -Adrenergic receptors, expression in heart, diabetes effects on, in rat, 455
- Advanced glycation end-product receptor functional gene promoter polymorphisms, 1505 p38 MAPK-dependent NF- κ B activation, 1495 putative genes, polymorphism screening of, 1214
- AGAT- α . *see* 1-Acyl-glycerol-3-phosphate acyltransferase- α
- Agouti-related protein chronic, effects in pair-fed animals, 248 mRNA levels, ghrelin effects on, in rat hypothalamus, 2438
- AICAR. *see* 5-Aminoimidazole-4-carboxamide-1- β -D-ribofuranoside
- AJ-9677, insulin resistance amelioration by, in KK-A^y/Ta diabetic obese mouse model, 113
- Albumin glomerular permeability response to ACE inhibition, 2619 synthesis of, insulin effects on, in swine model, 947 urinary excretion rate, and autonomic neuropathy in nondiabetic offspring of type 2 diabetic subjects, Fredericia Study, 630
- Albuminuria, antihypertensive therapy effects on renal structure in type 1 diabetic subjects with, 843
- Alcohol consumption, and type 2 diabetes risk among men, 2390
- Allogeneic islets, stable, reversal of streptozotocin-induced diabetes with, in type 1 model, 1227
- Allorecognition, indirect, in acquired thymic tolerance, 1546
- Allorejection, protection of islets against, by barium-alginate membrane, 1698
- Allotransplantation, islet, in type 1 diabetes, 277
- α -Cells clonal mouse α TC6 cells, exocytosis of l-glutamate by, 1012 plasma glucose changes and, in dog, 367 α TC6 cells, exocytosis of l-glutamate by, 1012
- American Diabetes Association, research funded by, year 2 status, 1222
- Amino acids, effects on free ADP in β HC9 insulin-secreting cells, 291
- Aminoaciduria, with HNF-1 α mutations, 2047
- Aminoguanidine, diabetic retinopathy inhibition by, 1636
- 5-Aminoimidazole-4-carboxamide-1- β -D-ribofuranoside chronic, effects on insulin-stimulated glucose uptake and GLUT4 translocation, in rat skeletal muscles, 12 effects on glucose and lipid metabolism, in rats, 1076
- AMP (adenosine monophosphate)-activated protein kinase activation of in insulin-resistant rats, 1076 in type 2 diabetes, 921 HNF-4 α target, 1515
- Amyloidosis, islet characteristics of, 2514 promotion by oophorectomy, in hIAPP-transgenic mice, S184
- Angiogenesis, stimulation by inhibition of lipid peroxidation, in genetically diabetic mouse, 667
- Angiogenic eye disease, pigment epithelium-derived factor loss in, 2641
- Angiopietin-2, induction by angiotensin II, in endothelial cells, 867
- Angiotensin II Ang-2 induction by, in endothelial cells, 867 oxidative stress, inhibition by IGF-1 overexpression, 1414 PKC translocation and, 1918
- Angiotensin-converting enzyme inhibitors albumin permeability response to, 2619 glomerular lesion modulation by, in diabetic nephropathy, 2619
- Animal studies. *see also specific species* pair-fed animals, chronic agouti-related protein and energy expenditure in, 248 pig-to-mouse fetal endocrine pancreas transplantation, differentiation of, 962 type 1 diabetes models, international workshop on lessons from, 2451
- Annexin I early glucose adduct formation by, in diabetes, 1666 gene, in type 2 diabetes, 2402

- Annexin II, early glucose adduct formation by, in diabetes, 1666
- Antibodies. *see* Autoantibodies
- Antigen, mucosal, diabetogenic CTL priming by, 771
- Antihypertensive therapy, renal structure effects, in type 1 diabetic subjects with albuminuria, 843
- Antioxidants
- effects on diabetic retinopathy, 1938
 - effects on endoneurial blood flow, motor nerve conduction velocity, and sciatic nerve arterioles, 1927
 - and plasma 8-hydroxyguanine levels in diabetic rats, 2837
- Apolipoprotein A-II, transgenic mice studies, 643
- Apolipoprotein B-48 lipoproteins, plasma, modulation by hyperinsulinism, 462
- Apolipoprotein C1, protection from obesity and insulin resistance by, in mice, 2779
- Apoptosis
- β -cell, S44
 - Bcl-2 and Bax- Ω downregulation and, in rat, S82
 - in diabetes, S44
 - imidazoline protection against, S70
 - induction by glucose, 1683
 - nuclear factor- κ B and, 2219
 - signaling of, S58
 - in type 1 diabetes, S64
 - in diabetes, S44
 - endothelial, in diabetes, 1472
 - induction by high glucose, in human islets, 1290
 - islet-cell
 - IL-1-induced, 551
 - induction by high glucose, in human cells, 1290 - modulation by glucose and palmitic acid, in rat cardiomyocytes, 2105
 - myocyte, hyperglycemia and p53 and, 2363
 - vascular smooth muscle cell, glucose metabolism association, 1171
- AR42J cells, differentiation of
- Na-Pi cotransporter expression during, S39
 - neurogenin 3 in, S10
- Ashkenazi Jews, genome scan for type 2 diabetes loci, 681
- Aspirin, diabetic retinopathy inhibition by, 1636
- Atherosclerosis
- diabetes-induced, in swine, 1654
 - risk factors, kidney-pancreas transplantation effects on, 496
 - smooth muscle accumulation in, in diabetic subjects, 851
- ATP-sensitive K^+ channels
- activation by insulin, in β -cells, 2192
 - in endocrine pancreas cell survival and differentiation, S48
 - nicorandil action on, 2253
- Autoaggressive lymphocytes, protection from, in transgenic mice, 2700
- Autoantibodies
- anti-CD38, human
 - in Caucasian diabetic subjects, 752
 - signaling properties of, 985
- GAD65
- human recombinant, from type 1 diabetes, 1976
 - in ICA+ relatives, 1735
 - insulin, in NOD mice, 2451
 - response to islet transplantation in type 1 diabetes, 2464
- seroconversion in siblings of children with type 1 diabetes, 2625
- Autoantigen
- IA-2
 - autoimmunity against, by IA-2 gene splicing in pancreas and lymphoid organs, 895
 - coding and promoter regions of, 2406
 - for T-cell workshops, 1749
- Autoimmune diabetes
- decrease by adenovirus genes, in NOD mice, 980
 - Idd5.1* mapping for, in NOD mice, 2874
 - pancreatic biopsy in, 1269
 - transgenic c-Maf effects on, 39
- Autoimmunity
- β -cell, reversible, in transgenic mice, 2260
 - chromosome 18 and, 184
 - against IA-2 type 1 diabetes autoantigen, by IA-2 gene splicing in pancreas and lymphoid organs, 895
- Autoislet transplantation
- long-term, 47
 - prevention of diabetes by, after pancreatectomy for chronic pancreatitis, 47
- Autonomic neuropathy, and parental diabetes, Fredericia Study, 630
- Autoreactive T-cells, detection of, in type 1 diabetes, 1749
- B**
- B9-23 peptide, insulin autoantibody induction by, in mice, 1274
- Barium currents, nerve growth factor and, 1755
- Barium-alginate membrane, protection of islets against allotransplantation by, 1698
- Bax-caspase-3 pathway, p38 MAPK phosphorylation downstream of, endothelial apoptosis and, 1472
- Bax- Ω , downregulation of, and rat β -cell apoptosis, S82
- BB rat thymocytes, 972, 2414
- Bcl-2
- downregulation of, and rat β -cell apoptosis, S82
 - in rat blastocysts, 143
- Benzylamine, combined with vanadate, in STZ-induced diabetic rats, 2061
- β -Cells
- acetyl-CoA carboxylase regulation in, 1580
 - adaptation to diabetes, S154
 - adaptation to glucose level changes, *c-myc* gene and, S137
 - adaptation to hyperglycemia, S180
 - adhesion to extracellular matrix, intracellular calcium and, 1039
 - apoptosis of, S44
 - Bcl-2 and Bax- Ω downregulation and, in rat, S82
 - in diabetes, S44
 - imidazoline protection against, S70
 - induction by glucose, 1683
 - nuclear factor- κ B and, 2219
 - signaling of, S58
 - in type 1 diabetes, S64
 - autoimmunity against, reversible, in transgenic mice, 2260
 - barium current in, nerve growth factor and, 1755
 - cytotoxic damage to, prevention by TIMP-1, 1047
 - death of
 - β -cells in, S52
- blockade by cell-permeable peptide JNK inhibitors, 77
 - decompensation in diabetes, S154
 - deficient mice, diabetogenic T cells in, 763
 - development of
 - early, in type 2 diabetes, in GK rat model, S84
 - IPF-1 and, S36 - differentiation of, S5
 - induction by GLP-1, 784
 - novel pancreatic precursor cell line for study of, S42
 - dysfunction of
 - in IRS-1 Gly972Arg, 882
 - PDX1 deficiency and, in *P. obesus*, 1799
 - in type 2 diabetes, S160, S169
 - in type 2 diabetes, evidence for, S172 - expansion of
 - by EGF, 1571
 - for type 2 diabetes treatment, S189 - Fas expression in, molecular regulation of, S83
 - function of
 - fatty acid effects on, 69
 - genetic factors, S84
 - in GK rat, S89
 - IRS proteins and, S140
 - metabolic effects of restoration after islet allotransplantation in type 1 diabetes, 277
 - metabolic factors, S84
 - oral glucose tolerance test minimal model index of, 150
 - overstimulation and, S122
 - in type 2 diabetes, S140 - gene expression monitoring, online, S15
 - gene expression profiling, S135
 - gene mutations, pathophysiology of, S101
 - glucose induction of hormone-sensitive lipase in, 2225
 - glucose sensing in, 1
 - glucotoxicity in *P. obesus* type 2 diabetes, S113
 - growth factors, S25
 - growth of, S5
 - GLP-1-induced, PKC ζ and, 2237 - hyperplasia in *Irs* knockout mice, S150
 - IFN- γ signaling in, 2744
 - insulin activation of K_{ATP} channels in, 2192
 - insulin receptor and, S146
 - insulin secretion in
 - BLI1282 and, 797
 - nerve growth factor and, 1755 - Kit* expression in, 2021
 - lipolysis in, GLP-1 and, 56
 - lipotoxicity of, S15
 - in obesity, S118
 - mass decrease in minipig, 2001
 - mass in type 2 diabetes, S140
 - preservation of, S188
 - reduction of, S169
 - mass in Zucker diabetic fatty rats, 1021
 - mass of, in vivo measurement of, in mouse model, 2231
 - mTOR-signaling pathway translation
 - initiation by, regulation by leucine, 353 - neogenesis of
 - by neonatal GLP-1 treatment, in rats, 1562
 - in type 2 diabetes, S186 - neutral lipid synthesis in, 315
 - nNOS in, insulin secretion regulation by, 1311, 2177
 - novel cytokine-induced genes in, identification by high-density oligonucleotide arrays, 909

- number in type 2 diabetes, S169
 p57^{KIP2} expression in, 2763
 PDX-1 shuttling in, 2244
 plasma glucose changes and, in dog, 367
 recruitment by glucose, 540
 secretory and metabolic pathway genes, regulation by glucose, S135
 sorting of, sialylated NCAM (PSA-NCAM) for, S125
 -specific insulin and PDX-1 expression, S131
 transcription defect in, in ZDF rat, 63
 transcription factor mutations, S94
 turnover of
 assessment and implications, S20
 fatty acid effects on, 69
 genetic and metabolic factors, S84
 UCP-2 overexpression in, 1302
 viability in GK rat, S89
- β HC9 insulin-secreting cells, free ADP in, 291
 Bezafibrate, and fatty acid oxidation in adipocytes, 1883
- Biopsy, pancreatic, in type 1 diabetes, 1269
- Birth weight, diabetes-associated HLA-DQ genes and, 2879
- BL11282, and insulin secretion in β -cells, 797
- Blastocysts, Bcl-2 in, in rat, 143
- Blood flow, endoneurial, antioxidant treatment and, 1927
- Blood pressure
 diurnal variation, QTc dispersion and, in diabetes, 837
 24-h ambulatory, and autonomic neuropathy in nondiabetic offspring of type 2 diabetic subjects, Fredericia Study, 630
- BMI, parent-of-origin effects in, genome-wide scan for, 2850
- Body weight
 cerulenin effects on, 733
 ghrelin effects on, in rat, 2438
- Bovine retinal endothelial cells, angiopoietin-2 induction by AII in, 867
- Brain
 acute hypoglycemia effects on, functional MRI study, 1618
 ¹⁸F-FDG uptake at hypoglycemia in, in type 1 diabetic men, 2329
 glucose transport in, insulin and, 2203
 BRL 49653, *see* Rosiglitazone
- C**
- Caffeine, and glucose disposal, 2349
- Calcium
 coronary artery, familial aggregation of, in type 2 diabetic families, 861
 cytoplasmic, in islet cell clusters, measurements of, 540
 -dependent exocytosis of l-glutamate by α TC6 cells, 1012
 intracellular
 and β -cell adhesion, 1039
 increase by human anti-CD38 autoantibodies, 985
 and Rab3A association with calmodulin, 2029
- Calcium-cycling proteins, and sarcoplasmic reticulum dysfunction, in diabetic heart, 2133
- Calmodulin, association with Rab3A, 2029
- Calpains, regulation of insulin secretion and action by, 2013
- Capillary recruitment, insulin-mediated exercise training and, in rat, 2659
 in muscle, in hyperinsulinemia, 2682
- CAPN10 gene, UCSNP-43 polymorphism, and insulin secretion, 2161
- Carbohydrates, metabolism of, liver-derived IGF-I and, 1539
- Carbon monoxide, vasorelaxant effects in diabetes, 166
- Cardiac surgery, nitric oxide metabolism during, diabetes and, 2603
- Cardiomyocytes, dysfunction of, with insulin resistance, in sucrose-fed rats, 1186
- Cardiomyopathy
 diabetic, inhibition by IGF-1 overexpression, 1414
 glucose, 2105
- Carnitine palmitoyltransferase-1, muscle, inhibition of, promotion of intramyocellular lipid accumulation and insulin resistance by, in rats, 123
- CART gene, mutations in obese children, 2157
- Caucasians
 diabetic, anti-CD38 autoantibodies in, 752
 women, adrenoceptor gene variants and obesity in, 91
- Caveolin, levels, in hypertensive rats, 2148
- C57BL/6J mice, diabetic embryopathy in, 1193
- CD38, anti-CD38 autoantibodies, human in Caucasian diabetic subjects, 752
 signaling properties of, 985
- CD40-CD154 pathway, blockade of, islet graft survival prolongation by, in NOD mice, 270
- CD154
 CD40-CD154 pathway, blockade of, islet graft survival prolongation by, in NOD mice, 270
 hamster anti-murine mAb MR1, chronic, islet graft survival prolongation by, in NOD mice, 270
- C/EBP, and Fas regulation by cytokines, 1741
- Cell death, *see* Apoptosis
- Cell differentiation
 AR42J cell
 Na-Pi cotransporter expression during, S39
 neurogenin 3 in, S10
 β -cell, S5
 novel pancreatic precursor cell line for study of, S42
- Endocrine
 ATP-sensitive K⁺ channels in, S48
 in transplanted human islets, 301
 of nestin-positive stem cells from adult islets, 521
 pancreatic islet, ATP-sensitive K⁺ channels in, S48
 preadipocyte, inhibition by indinavir, 1378
 of transplanted fetal endocrine pancreas, in pig-to-mouse model, 962
- Cell growth
 β -cell, S5
 GLP-1-induced, PKC ζ and, 2237
 endocrine, in transplanted human islets, 301
 insulin activation of PKC δ in, 255
 insulin-producing cell, inhibition by STAT5, S40
 VSM cell, stimulation by hypoxia, 1482
- Cell proliferation, *see* Cell growth
- Cell-replacement therapy, for type 1 diabetes, 2181
- Cephalic insulin response to meal ingestion, in humans, 1030
- Ceramide, insulin resistance by, 2563
- Cerebellar granule cells, type 1 diabetic serum effects on, S77
- Cerebral glucose, insulin and, 2203
- Cerulenin, mechanism of action, 733
- Children, prepubertal, insulin sensitivity and fat in, 477
- Chinese subjects, with late-onset type 2 diabetes, *IRS-2* gene in, 1949
- Chloride channels, HIT cell volume regulation by, 992
- Cholesterol, metabolism of, regulation by insulin and leptin, 955
- Cholesterol absorption inhibitors, ezetimibe, normalization of combined dyslipidemia by, in obese hyperinsulinemic hamsters, 1330
- Chromosome 3
 Idd10 and *Idd18* loci on, mapping by genetic interaction, in NOD mice, 2633
 RAGE gene 5' regulatory region, variation with chromosome 6 RAGE gene, 2646
- Chromosome 6, RAGE gene on, variation with chromosome 3 5' regulatory region, 2646
- Chromosome 18p11, type 2 diabetes loci, genome scan for, 675, 1512
 in Ashkenazi Jews, 681
- Chromosome 12q15, type 2 diabetes locus on, 204
- Chromosome 18q12-q21, association with autoimmunity, 184
- Cigarette smoking, and microalbuminuria onset in type 1 diabetes, 2842
- Circadian variations
 in blood pressure, QTc dispersion and, in diabetes, 837
 in glucose tolerance, 1237
- c-Jun NH₂-terminal kinase
 activity in insulin-secreting cells, 2721
 cell-permeable peptide inhibitors of, 77
- Clonal mouse α cells, α TC6 cells, exocytosis of l-glutamate by, 1012
- c-Maf, transgenic, effects on autoimmune diabetes, 39
- c-myc gene, in β -cell adaptation to glucose level changes, S137
- Collagen, platelet activation, induction by hyperglycemia, 1491
- α 1(IV) Collagen, ET-1 activation of, high glucose-enhanced, in mesangial cells, 2376
- Combined dyslipidemia, normalization by ezetimibe, in obese hyperinsulinemic hamsters, 1330
- Complementary DNA arrays, for gene identification in suckling rat islets, 2053
- Congenital hyperinsulinism, insulin dysregulation in, 322
- Conjugated linoleic acid, antidiabetic properties of, 1149
- Contraction
 skeletal muscle, insulin p38 MAPK α and β activation and, in rat, 478
 -stimulated glucose transport, inhibition by indinavir, in skeletal muscle, 1397
- Copper, Cu²⁺/Zn²⁺ superoxide dismutase, protection against early diabetic glomerular injury in transgenic mice by, 2114
- Coronary artery calcium
 familial aggregation of, in type 2 diabetic families, 861
 lipid transfer protein activities and, in type 1 diabetes, 652
- Coronary microvascular dilation, in type 2 diabetes, 1180
- Corticotropin-releasing hormone, secretion of, modulation by galanin, 2666
- Counter-regulatory failure, FDG-PET in, 2329
- C-peptide, stimulation by decreased fasting and oral glucose, with SUR1 sequence variants, 697

- Creatine, oral supplementation, effects on human muscle GLUT4 protein content, 18
- CTLA4* gene, point mutation in West African type 1 diabetes patients, 2169
- Cyclic stretch, retinal VEGF-R2 expression, 444
- Cystic fibrosis, protein metabolism in, 1336
- Cytokines
- β -cell apoptosis, Bcl-2 and Bax- Ω downregulation and, in rat, S82
 - Fas regulation by, 1741
- Cytoplasmic calcium, in islet cell clusters, measurements of, 540
- Cytotoxic T-lymphocytes, diabetogenic, priming by mucosal antigen, 771
- Cytotoxicity
- free fatty acid, in islet cells, 1771
 - islet, prevention by TIMP-1, 1047
- D**
- Daily rhythms
- in blood pressure, QTc dispersion and, in diabetes, 837
 - in glucose tolerance, 1237
- Decompensation, β -cell, in diabetes, S154
- Dendritic cells, alloptide-primed, tolerance by, 1546
- 2-Deoxy-d-glucose, abolishment of glucoprivic responses by, 2831
- Dephosphorylation, insulin receptor, in rat adipocytes, 83
- Dexamethasone, abolishment of glucoprivic responses by, 2831
- Diabetes
- accelerated atherosclerosis with, in swine, 1654
 - amelioration by GLUT4 overexpression, in *db/db* mice, 593
 - animal models. *see* Animal studies; *specific animals*
 - apoptosis in, S44
 - autoimmune
 - Idd5.1* mapping for, in NOD mice, 2874
 - transgenic c-Maf effects on, 39 - β -adrenoceptor expression in rat hearts with, 455
 - β -cell adaptation to, S154
 - β -cell death in, S44
 - β -cell decompensation in, S154
 - β -cell mass in, in vivo measurement of, in mouse model, 2231
 - decrease by adenovirus genes, in NOD mice, 980
 - endothelial apoptosis in, 1472
 - endothelial plasma membrane glycation in, 1666
 - lipotrophic, rescue by transgenic leptin, in mouse model, 1440, 1675
 - maternal, altered nephrogenesis due to, IGF-II/M6PR in, 1069
 - maturity-onset
 - associated *ACVR2B* mutations, in French patients, 1219
 - NEUROG3* mutations and, in Japanese subjects, 694 - microencapsulated islet survival in, in NOD mice, 1698
 - natural killer T-cell deficiency in, in NOD mice, 2691
 - and nitric oxide during cardiac surgery, 2603
 - parental, autonomic neuropathy and, Fredericia Study, 630
 - phenotypic correction by adenoviral glucokinase expression, in mice, 2287
 - phogrin T-cell epitopes in, in NOD mice, 1729
 - PKC ϵ overexpression in skeletal muscle before, 584
 - polymorphic studies in, 2646
 - prevention by autoislet transplantation after pancreatectomy for chronic pancreatitis, 47
 - resistance to, PPAR- γ Ala¹² variant and, 891
 - retinal metabolism in, 1938
 - sarcoplasmic reticulum dysfunction in, 2133
 - smooth muscle accumulation in atherosclerotic lesions with, 851
 - SREBP-1c and glucose homeostasis in mice with, 2425
 - streptozotocin-induced
 - plasma 8-hydroxyguanine levels in, in rats, 2837
 - reduction by metallothionein, 2040
 - reversal with stable allogeneic islet function, in type 1 model, 1227 - sustained NF- κ B activation associated with, 2792
 - type 1. *see* Type 1 diabetes
 - type 2. *see* Type 2 diabetes
 - vasorelaxant effects of CO in, 166
- Diabetes Prevention Trial-Type 1, eligibility for, GAD65 autoantibodies in ICA+ relatives and, 1735
- Diabetic cardiomyopathy, inhibition by IGF-1 overexpression, 1414
- Diabetic embryopathy, in C57BL/6J mice, 1193
- Diabetic heart, insulin signaling in, in rat, 2709
- Diabetic nephropathy
- candidate gene screening in, 1214
 - glomerular lesions in, modulation by ACE inhibitors, 2619
- Diabetic neuropathy, vascular dysfunction in, 1927
- Diabetic retinopathy
- antioxidant effects on, 1938
 - functional RAGE promoter polymorphisms and, 1505
 - IGF-I signaling in, 175
 - inhibition by aminoguanidine and aspirin, 1636
 - microthromboses in, 1432
- Diabetogenic T cells
- in β -cell-deficient mice, 763
 - cytotoxic, priming by mucosal antigen, 771
- Diet
- high-fat, -induced insulin resistance, in PPAR- α -null mice, 2809
 - induced type 2 diabetes, rebred Cohen rat model of, 2521
- Dilation, coronary vasodilation, in type 2 diabetes, 1180
- Dipeptidyl peptidase IV, inhibition of, and glucose-dependent insulintropic peptide, in pigs, 1588
- Diurnal variations
- in blood pressure, QTc dispersion and, in diabetes, 837
 - in glucose tolerance, 1237
- Dog studies
- α - and β -cell responses to non-insulin-induced hypoglycemia in, 367
 - denervated pancreas response to mild hypoglycemia, 2487
 - low-dose insulin and hypoglycemia in, 558
- Dopamine receptor D2 gene, Ser311Cys mutation, and energy expenditure, 901
- Drinking patterns, and type 2 diabetes risk among men, 2390
- Dyslipidemia
- combined, normalization by ezetimibe, in obese hyperinsulinemic hamsters, 1330
 - of insulin resistance, hepatic proteoglycans and, 2126
- E**
- Early response genes. *see specific genes*
- Edmonton protocol, islet transplantation with, outcomes and insulin secretion after, 710
- Efaroxan, insulin secretion potentiation by, K_{ATP} channel-independent, 340
- Elderly, inflammation markers and glucose disorders in, 2384
- Electrocardiography, QTc dispersion, and diurnal BP variations, in diabetes, 837
- Embryonic cells, pancreatic, expansion by EGF, 1571
- Embryonic stem cells, insulin production by, 1691
- Embryopathy, diabetic, in C57BL/6J mice, 1193
- Endocrine cells, proliferation and differentiation in transplanted human islets, 301
- Endocrine pancreas
- cell survival and differentiation, ATP-sensitive K⁺ channels in, S48
 - fetal, ontogeny of, 962
 - in insulin receptor-deficient mouse pups, S146
 - nestin-positive stem cell differentiation into, from adult islets, 521
 - plasticity of, S30
 - transplanted fetal, differentiation of, in pig-to-mouse model, 962
- Endoneurial blood flow, antioxidant treatment and, 1927
- Endothelial cells
- angiopoietin-2 induction by AII in, 867
 - apoptosis of, in diabetes, 1472
 - glycated LDL uptake in, mediation by lipoprotein lipase, 1643
- Endothelial dysfunction, induction in obesity, 159
- Endothelial function
- insulin-stimulated, in type 2 diabetic patients with ischemic heart disease, 2611
 - kidney-pancreas transplantation effects on, 496
- Endothelial insulin resistance, in type 2 diabetic patients with ischemic heart disease, 2611
- Endothelial plasma membrane glycation, in diabetes, 1666
- Endothelin-1, ERK1/2 and α 1(IV) collagen activation by, high glucose-enhanced, in mesangial cells, 2376
- Energy expenditure
- chronic agouti-related protein and, in pair-fed animals, 248
 - DRD2 gene and, 901
- Energy fuels, channeling toward fat *vs* muscle during high free fatty acid availability, in rats, 601
- Epidermal growth factor
- oral wound healing reversal by, in NOD mice, 2100
 - pancreatic embryonic cell expansion by, 1571
- European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT), antihypertensive therapy effects on renal structure in type 1 diabetes with albuminuria, 843
- Exercise

- AMPK activation during, in type 2 diabetes, 921
- bicycle, effects on GSK3 regulation in skeletal muscle, 265
- glucose kinetics during glucosamine and, in rats, 139
- insulin secretion and, 1834
- resistance to, in insulin-resistant skeletal muscle, in type 1 diabetes, 1371
- Exercise training, and insulin action, in rat, 2659
- Exocrine pancreas
- monocarboxylate transporter expression and distribution in, 361
 - nestin-positive stem cell differentiation into, from adult islets, 521
 - PDX-1 misexpression in, glucose tolerance and acinar dysmorphogenesis by, 1553
- Extracellular matrix, β -cell adhesion to, intracellular calcium and, 1039
- Extracellular signal-regulated protein kinase ERK1/2, ET-1 activation of, high glucose-enhanced, in mesangial cells, 2376
- Eye disease, angiogenic, pigment epithelium-derived factor loss in, 2641
- Ezetimibe, normalization of combined dyslipidemia by, in obese hyperinsulinemic hamsters, 1330
- F**
- Familial combined hyperlipidemia, gene effects on insulin sensitivity in, 2396
- Families
- siblings of type 1 diabetic children, autoantibody seroconversions in, 2625
 - with type 2 diabetes
 - familial aggregation of coronary artery calcium in, 861
 - GIP insulinotropic effects in, 2497
 - glucose-intolerant relatives, skeletal muscle insulin signaling in, 2770
 - insulin receptor signaling in, 2572
 - lactate release per fat cell in, 2344
- Fas
- expression in β -cells, molecular regulation of, S83
 - function in polyreactive type 1 diabetes, 483
 - regulation by cytokines, 1741
- Fas receptor, upregulation by glucose, 1683
- Fasting
- decreased, C-peptide stimulation by, with SUR1 sequence variants, 697
 - protein-retaining effects of growth hormone during, 96
- Fasting insulin, gene effects on, in familial combined hyperlipidemia, 2396
- Fat. *see also* Adipose tissue
- abdominal, genome-wide scan for, in Québec Family Study, 614
 - accumulation of reduction by central histamine infusion, in leptin-resistant obese mice, 377
 - gene expression in, nonesterified fatty acids and, in rats, 601
 - high-fat
 - induced insulin resistance, in PPAR- α -null mice, 2809
 - insulin signaling in muscle in rats on, 1901
 - insulin sensitivity and, in prepubertal children, 477
 - intramyocellular content, plasma FFAs and, 1612
 - lactate release per cell, in type 2 diabetic relatives, 2344
 - omental, gene expression profiling of, 2822
- Fatty acids. *see also* Free fatty acids
- effects on β -cell turnover and function, 69
 - induced peripheral tissue insulin resistance, susceptibility to, in women, 1344
 - and liver proteoglycans, 2126
 - metabolism in insulin-resistant muscle of Zucker diabetic fatty rats, 1389
 - nonesterified, and gene expression, in fat and muscle, in rats, 601
 - oxidation in adipocytes, bezafibrate and, 1883
 - regulatory effects on macrophage lipoprotein lipase, 660
 - spillover of, causes of, β -cell lipotoxicity in, S118
 - uptake in insulin-resistant muscle of Zucker diabetic fatty rats, 1389
- Fatty liver disease, nonalcoholic, 1844
- Feeding
- high-sucrose, neuropeptide Y overexpression and obesity after, 1206
 - regulatory effects of leptin on, H_1 -receptor disruption and, in mice, 385
- Fetal endocrine pancreas
- ontogeny of, 962
 - transplanted, differentiation of, in pig-to-mouse model, 962
- Fetal kidney, diabetes-impaired, IGF-II/M6PR in, 1069
- Fetal sex ratio, in C57BL/6J mice, 1193
- Fibrinogen, synthesis of, insulin effects on, in swine model, 947
- Fibroblasts, glycated LDL uptake in, mediation by lipoprotein lipase, 1643
- Fibronectin, synthesis of, hexosamines and, in mesangial cells, 2355
- Finnish subjects, with late-onset type 2 diabetes, *IRS-2* gene in, 1949
- Fizz3, expression in humans, 2199
- Flotillin, levels in hypertensive rats, 2148
- ^{18}F -Fluorodeoxyglucose, uptake at hypoglycemia in type 1 diabetic men, 2329
- Food intake
- cerulenin effects on, 733
 - effects on GSK3 regulation in skeletal muscle, 265
- Fredericia Study, autonomic neuropathy and parental diabetes, 630
- Free fatty acids
- cytotoxicity of, in islet cells, 1771
 - effects on gluconeogenesis, in type 2 diabetes, 810
 - effects on insulin secretion and sensitivity in PPAR- γ_2 Pro12Ala, 1143
 - effects on intramyocellular fat content, 1612
 - effects on splanchnic glucose uptake, in men, 727
 - and GH-induced insulin resistance, 2301
 - high availability, energy fuel channeling toward fat vs muscle during, in rats, 601
 - insulin resistance by
 - prevention by thiazolidinedione, in male Wistar rats, 2316
 - in rats, 418
 - plasma uptake and oxidation in subjects at high-risk for type 2 diabetes, 2548
 - plasma-adipose tissue exchange capacity, thiazolidinedione effects on, 1158
 - systemic availability of, insulin-mediated control of, thiazolidinedione effects on, 1158
 - and UCP2, in insulin secretion, 803
- French patients, diabetes-associated *ACVR2B* mutations in, 1219
- Fructosamine-3-kinase, human, 2139
- Fructose, stimulation of hepatic glycogen synthesis by, in humans, 1263
- Fusion proteins, transduction of islets with, 1706
- G**
- GAD65, preparation for detection of autoreactive T-cells, in type 1 diabetes, 1749
- GAD65 autoantibodies
- human recombinant, from type 1 diabetes, 1976
 - in ICA+ relatives, 1735
- Galactosemia, retinal metabolism in, 1938
- Galanin, corticotropin-releasing hormone and neuropeptide Y secretion modulation by, 2666
- Gamma globulin, levels, and type 2 diabetes, in Pima Indian population, 1598
- Ganglion neurons, intrapancreatic, modulation of insulin pulses by, 51
- Gastric inhibitory polypeptide, insulinotropic effects in type 2 diabetic patient relatives, 2497
- Gene expression
- β -cell
 - expression profiling, S135
 - online monitoring of, S15
 - in fat and muscle, nonesterified fatty acids and, in rats, 601
 - hepatic, leptin and, in obese mice, 2268
 - insulin, glucose-regulated, and PDX-1 deficiency, in *P. obesus* type 2 diabetes, S138
 - regulation by insulin, in human skeletal muscle and adipose tissue, 1134
 - in suckling rat islets, 2053
 - tetracycline-inducible (Tet-On), in MIN6 cells, S133
- Gene expression profiling, of omental fat, 2822
- Gene mutations. *see* Mutations
- Gene polymorphism
- adrenoceptor variants, and obesity, in Caucasian women, 91
 - CAPN10 UCSNP-43, and insulin secretion, 2161
 - GYS1 XbaI*, and skeletal muscle glycogen synthase content, 195
 - HSLi6, and lipolytic function, 2410
 - IGF-I, 637
 - single nucleotide
 - CAPN10 UCSNP-43, and insulin secretion, 2161
 - of PC-1, in insulin resistance, 1952
- Gene therapy, for type 1 diabetes, 2181
- Gene transcription, defect in ZDF rat β -cells, 63
- Genes
- β -cell
 - novel cytokine-induced, identification by high-density oligonucleotide arrays, 909
 - regulation by glucose, S135
 - diabetes-associated HLA-DQ, and birth weight, 2879
 - in glucose-stimulated insulin secretion, S134
 - HDL, transcriptional regulation by glucose, 1850
 - p53-related, activation by hyperglycemia, 2363
- Genetic interaction, *Idd10* and *Idd18* mapping by, in NOD mice, 2633

- Genetics
 of β -cell function and turnover, S84
 candidate gene screening in diabetic nephropathy, 1214
 of HbA_{1c} levels in type 1 diabetes, 2858
 of insulin resistance in polycystic ovary syndrome, 2164
 of insulin sensitivity in familial combined hyperlipidemia, 2396
- Genome-wide linkage analysis, for parent-of-origin effects, 2850
- GFAT1. *see* Glutamine:fructose-6-phosphate amidotransferase-1
- Ghrelin
 circulating levels in obesity, 707
 hyperphagia and obesity caused by, in rats, 2540
 hypothalamic effects in rats, 2438
 hypothalamic NPY/Y1 receptor pathway activation by, 227
 plasma levels, preprandial surges, 1714
- GIP. *see* Glucose-dependent insulintropic polypeptide
- GK. *see* Glucokinase
- Gliclazide, and pulsatile insulin secretion, in type 2 diabetes, 1778
- Glomerular injury
 early diabetic, SOD-1 protection against, in transgenic mice, 2114
 lesions, modulation by ACE inhibitors, in diabetic nephropathy, 2619
- Glomerulus, albumin permeability in response to ACE inhibition, 2619
- Glucagon, secretion of, regulation by GLUT2-dependent sensors, 1282
- Glucagon-like peptide-1
 β -cell differentiation induction by, 784
 β -cell growth induced by, PKC ζ and, 2237
 and β -cell lipolysis, 51
 and hepatoportal vein glucose sensing, 1720
 neonatal treatment, β -cell neogenesis by, in rats, 1562
 postprandial levels, in type 2 diabetes, 609
 and pulsatile insulin secretion, in type 2 diabetes, 776
- Glucagon-like peptide-1 derivative NN2211, weight loss therapy with, 2530
- Glucagon-like peptide-1(7–36)-amide, effects in type 1 diabetes, 565
- Glucokinase
 adenoviral, phenotypic correction of diabetes by, in mice, 2287
 gene locus transgenic mice, resistance to obesity-induced type 2 diabetes in, 622
 hepatic activity, in type 2 diabetes, 1351
 increased, prevention of type 2 diabetes by, 622
 mutations, pathophysiology of, S101
- Glucokinase regulatory protein, adenoviral Av3hGKRP, for type 2 diabetes, 1813
- Gluconeogenesis
 free fatty acid effects on, in type 2 diabetes, 810
 hyperinsulinemia effects on, 1807
 in small intestine, in rat, 740
- Glucoprivation, responses to, 2DG or dexamethasone abolishment of, 2831
- Glucosamine, and exercise-stimulated glucose turnover, in rats, 139
- Glucose
 apoptosis induction by
 in β -cells, 1683
 in human islets, 1290
 in rat cardiomyocytes, 2105
 autoregulation of, free fatty acid effects on, in type 2 diabetes, 810
 β -cell adaptation to changes in level of, *c-myc* gene and, S137
 β -cell recruitment by, 540
 β -cell secretory and metabolic pathway gene regulation by, S135
 cerebral levels, 2203
 disappearance constant, 690
 disposal of, 2349
 early adduct formation by endothelial plasmalemma-associated proteins, in diabetes, 1666
 endogenous production of, suppression of, insulin sensitivity of, 1449
 during exercise, 1834
 exercise-stimulated turnover of, glucosamine and, in rats, 139
 Fas receptor upregulation by, 1683
 free ADP effects in β HC9 insulin-secreting cells, 291
 glycogen synthesis regulation by, in human muscle cells, 720
 growth-promoting effects in diabetic subjects, 851
 HDL gene transcription regulation by, 1850
 hepatoportal vein sensing of, GLP-1 and, 1720
 high glucose-enhanced ET-1 activation of ERK1/2 and α 1(IV) collagen, in mesangial cells, 2376
 homeostasis of, SREBP-1c and, in diabetic mice, 2425
 hormone-sensitive lipase induction by, in β -cells, 2225
 insulin gene expression regulated by, and PDX-1 deficiency, in *P. obesus* type 2 diabetes, S138
 insulin secretion induced by
 free fatty acids and UCP2 in, 803
 genes in, identification of, S134
 hormone-sensitive lipase role in, 1970
 model for, S164
 and lipid metabolism, 1402
 metabolism of
 AICAR effects on, in rats, 1076
 hepatic, insulin effects on, 1872
 IGFBP-1 phosphorylation and, in IGFBP-1 transgenic mice, 32
 and pulsatile insulin release, 1785
 renal, in humans, 747
 and SUR1 sequence variants, 697
 and VSMC apoptosis, 1171
 myofibril degeneration induction by, in rat cardiomyocytes, 2105
 oral, C-peptide stimulation by, with SUR1 sequence variants, 697
 PKC activation by, angiotensin II and, 1918
 plasma
 α -cell responses to, in dog, 367
 β -cell responses to, in dog, 367
 decrease by tramadol, in diabetic rats, 2815
 renal handling in hypoglycemia, 2087
 renal release of, measurements of, 905
 skin keratinocyte effects, 1627
 uptake of
 exercise-induced, resistance to, in insulin-resistant skeletal muscle, in type 1 diabetes, 1371
 insulin-stimulated, effects of chronic AICAR treatment on, in rat skeletal muscles, 12
 NO-stimulated, in rat skeletal muscle, 241
 regulation by p38 MAPK, 1464
 splanchnic
 free fatty acid effects on, in men, 727
 GLP-1 effects on, in type 1 diabetes, 565
 in type 2 diabetes, 1351
 stimulation by α -lipoic acid, 1464
 D-Glucose, high exposure to, Bcl-2 in rat blastocysts after, 143
 Glucose disorders, inflammation markers and, in elderly, 2384
 Glucose sensing
 in β -cells, 1
 portal vein glucosensor locus, confirmation of, 399
 Glucose tolerance. *see also* Oral glucose tolerance test
 abnormal, protein metabolism in cystic fibrosis patients with, 1336
 with conjugated linoleic acid, 1149
 daily rhythm in, 1237
 impaired
 free fatty acid uptake and oxidation in, 2548
 GLP-1 and pulsatile insulin secretion in type 2 diabetic subjects with, 776
 improvement by PDX-1 misexpression in exocrine pancreas, 1553
 insulin sensitivity of endogenous glucose production suppression and, 1449
 Glucose transport
 blood-to-brain, after hypoglycemia, 1911
 brain, 2203
 impaired, phosphorylation interactions, in insulin resistance, 2069
 inhibition by indinavir, in skeletal muscle, 1397
 PED/PEA-15 effects on, mediation by PKC- α , in L6 skeletal muscle cells, 1244
 in skeletal muscle, in hypertensive rats, 2148
 Glucose transporter 2, glucagon secretion regulation by, 1282
 Glucose transporter 4
 activation of, p38 MAPK in, 1464
 cell surface, in transgenic mice, 593
 expression in type 2 diabetes and obesity, 1324
 human muscle, oral creatine supplementation and, 18
 overexpression effects, in *db/db* mice, 593
 in slow muscle fibers, in type 2 diabetes, 1324
 translocation
 effects of chronic AICAR treatment on, in rat skeletal muscles, 12
 by troglitazone, in L6 myotubes, 1093
 by troglitazone, in rat adipocytes, 2296
 Glucose-dependent insulintropic peptide, dipeptidyl peptidase IV inhibition and, in pigs, 1588
 Glucose-dependent insulintropic polypeptide, postprandial levels, in type 2 diabetes, 609
 Glucose-dependent insulintropic polypeptide receptor, expression of, in diabetic fatty Zucker rats, 1004
 Glucose-intolerant relatives, with type 2 diabetes, skeletal muscle insulin signaling in, 2770
 Glucosensing neurons, in ventromedial hypothalamic nucleus, 2673
 Glucose-6-phosphatase
 inhibition of, lipid metabolism effects, 2591
 islet-specific catalytic subunit-related protein gene promoter, mouse, *in situ* footprinting of, 502
 mechanism of, 1531
 reduction by GSK-3 inhibitors, 937

- substrate-transport model of, novel arguments in favor of, 1531
- Glucose-sensitive neurons, orexin A excitement of, in rat hypothalamus, 2431
- Glucotoxicity, β -cell, in *P. obesus* type 2 diabetes, S113
- GLUT, *see* Glucose transporter
- L-Glutamate, Ca^{2+} -dependent exocytosis of, by αTC6 cells, 1612
- Glutamate-sensitive protein phosphatase, acetyl-CoA carboxylase activation by, in β -cells, 1580
- Glutamine:fructose-6-phosphate amidotransferase-1, muscle-selective expression, 2419
- Glycemia
- effects on hepatic glycogen metabolism in type 1 diabetes, 392
 - postprandial, cephalic insulin response to meal ingestion and, in humans, 1030
- Glycerol, proinsulin biosynthesis by, in rat islets, 1791
- Glycogen
- glycogen synthesis regulation by, in human muscle cells, 720
 - metabolism of hepatic
 - stimulation by fructose, in humans, 1263
 - in type 1 diabetes, 392
 - insulin effects on, 1872
 - synthesis of
 - inhibition by palmitate, 2210
 - regulation by glucose, glycogen, and insulin, in human muscle cells, 720
- Glycogen synthase, skeletal muscle content, *GYS1 XbaI* gene polymorphism and, 195
- Glycogen synthase gene *GYS1 XbaI* gene polymorphism, and skeletal muscle glycogen synthase content, 195
- Glycogen synthase kinase-3, regulation of, in skeletal muscle, 265
- Glycogen synthase kinase-3 inhibitors, and type 2 diabetes, 937
- Glycogen synthase kinase-3 β , effects in glucose metabolism coupling with VSMC apoptosis, 1171
- Growth factors, β -cell, S25
- Growth hormone
- induced insulin-producing cell proliferation, inhibition by STAT5, S40
 - insulin resistance induction by, 1891
 - free fatty acids and, 2301
 - protein-retaining effects during fasting, 96
- GSN. *see* Glucose-sensitive neurons
- H**
- Hamster studies
- anti-murine hamster mAb MRI, chronic, islet graft survival prolongation by, in NOD mice, 270
 - obese hyperinsulinemic hamsters, combined dyslipidemia in, normalization by ezetimibe, 1330
- Heme oxygenase-1, induction of, and islet graft function, 1983
- HbA_{1c}, levels in type 1 diabetes, 2858
- HDL. *see* High-density lipoprotein
- Heart, diabetic
- β -adrenoceptor expression in, in rat, 455
 - disease inhibition by IGF-1 overexpression, 1414
 - insulin signaling in, in rat, 2709
 - with ischemic heart disease, endothelial insulin resistance in, 2611
 - sarcoplasmic reticulum dysfunction in, 2133
- Heart surgery, diabetes and nitric oxide metabolism during, 2603
- Hepatic artery, detection of hypoglycemia in, 399
- Hepatic nuclear factor-1 α , mutations, pathophysiology of, S101
- Hepatic phenotypes, differentiation of nestin-positive stem cells from adult islets into, 521
- Hepatic steatosis, G6Pase inhibition and, 2591
- Hepatocyte growth factor, effects on islet function and transplantation outcomes in mice, 2752
- Hepatocyte nuclear factor-1 α mutations, aminoaciduria with, 2047
- and pancreatic islet development and metabolism, 2472
- Hepatocyte nuclear factor-4 α , AMPK targeting, 1515
- Hepatoportal vein, glucose sensing of, GLP-1 and, 1720
- HepG2 cells, insulin-mediated PAI-1 signal transduction in, 1522
- Hexokinase, isozyme distribution in human skeletal muscle, 1253
- Hexosamines
- and fibronectin synthesis, in mesangial cells, 2355
 - insulin resistance and, in rats, 418
- High-density lipoprotein
- effects in adiposity and insulin resistance, in apoA-II transgenic mice, 643
 - transcriptional regulation by glucose, 1850
- High-density oligonucleotide arrays, identification of novel cytokine-induced genes in β -cells by, 909
- Histamine, central infusion of, in leptin-resistant obese mice, 377
- Histamine H₁-receptor, disruption of, and leptin regulatory effects, in mice, 385
- HIT cell volume, regulation by chloride channels, 992
- Homeobox. *see* Pancreatic duodenal homeobox-1
- Hormonal regulation, of β -cell mass, S25
- Hormone-sensitive lipase
- glucose induction of, in β -cells, 2225
 - in glucose-stimulated insulin secretion, 1970
- HSL16 gene polymorphism, and lipolytic function, 2410
- HSL. *see* Hormone-sensitive lipase
- Human lymphocyte antigen *HLA-DPB1*, and type 1 diabetes, 1200
- Human lymphocyte antigen *HLA-DQ*, diabetes-associated genes, and birth weight, 2879
- Human yolk sac, insulin imprinting in, 199
- 8-Hydroxyguanine, plasma levels, in diabetic rat, 2837
- Hyperglucagonemia, β -cell mass decrease and, in minipig, 2001
- Hyperglycemia
- β -cell adaptation to, S180
 - and increased islet TAG content, in Zucker diabetic fatty rats, 2481
 - and insulin gene mRNA levels, in Zucker diabetic fatty rats, 2481
 - and insulin release in GK rat islets, S108
 - insulin resistance in, insulin receptor dephosphorylation in, in rat adipocytes, 83
 - and microalbuminuria onset in type 1 diabetes, 2842
 - p53 activation by, 2363
 - PKC ϵ overexpression in skeletal muscle before, 584
- platelet activation induction by, 1491
- and VSM cell growth stimulation by hypoxia, 1482
- Hyperinsulinemia
- capillary recruitment by insulin in muscle in, 2682
 - clamp in lipoprotein lipase-transgenic mice, 2585
 - and gluconeogenesis, 1807
 - PKC ϵ overexpression in skeletal muscle before, 584
 - resistance to exercise-induced glucose uptake in insulin-resistant skeletal muscle during, in type 1 diabetes, 1371
- Hyperinsulinemic hypoglycemia of infancy, persistent, focal, S182
- Hyperinsulinism
- acute, plasma apoB-48 lipoprotein modulation by, 462
 - congenital, insulin dysregulation in, 322
 - of infancy, 329
 - p57^{KIP2} expression in β -cells in, 2763
- Hyperlipidemia, familial combined, gene effects on insulin sensitivity in, 2396
- Hyperphagia, caused by ghrelin, in rats, 2540
- Hyperplasia, reversible β -cell autoimmunity and, in transgenic mice, 2260
- Hypertension
- muscle glucose transport in, in rats, 2148
 - retinal VEGF-R2 expression in, 444
- Hypoglycemia
- acute, effects on brain, functional MRI study, 1618
 - and adrenal sympathetic activity, in rats, 1119
 - blood-to-brain glucose transport after, 1911
 - detection of, in hepatic artery or liver, 399
 - ¹⁸F-FDG uptake at, in type 1 diabetic men, 2329
 - hypothalamic orexin-B level increase by, 105
 - low-dose insulin and, in dog, 558
 - mild, pancreatic response to, 2487
 - non-insulin-induced
 - α -cell responses to, in dog, 367
 - β -cell responses to, in dog, 367
 - orexin neuron activation by, 105
 - persistent hyperinsulinemic of infancy, focal, S182
 - portal vein glucosensor locus for, confirmation of, 399
 - renal glucose handling in, 2087
- Hypothalamic nucleus, ventromedial, glucosensing neurons in, 2673
- Hypothalamus
- ghrelin effects on, in rat, 2438
 - glucose-sensitive neurons, orexin A excitement of, in rat, 2431
 - neuropeptide Y/Y1 receptor pathway, activation by ghrelin, 227
 - orexin-B levels, increase by hypoglycemia, 105
- Hypoxia, VSM cell growth stimulation by, 1482
- I**
- IA-2. *see* Insulinoma-associated tyrosine phosphatase-like protein
- Idd5.1* gene locus, mapping of, for autoimmune diabetes in NOD mice, 2874
- Idd10* gene locus, mapping by genetic interaction, in NOD mouse, 2633
- Idd18* gene locus, mapping by genetic interaction, in NOD mouse, 2633
- idDM1* gene locus, *HLA-DPB1*-associated component of, and type 1 diabetes, 1200

- IDX-1. *see* Islet duodenal homeobox-1
 IGRP. *see* Islet-specific glucose-6-phosphatase catalytic subunit-related protein gene promoter
 Imidazole
 novel compound BL11282, and insulin secretion in β -cells, 797
 protection against β -cell apoptosis, S70
 In situ footprinting, of mouse IGRP gene promoter, 502
 Indinavir
 glucose transport inhibition by, in skeletal muscle, 1397
 insulin resistance and, 1397
 preadipocyte differentiation inhibition by, 1378
 Infancy
 hyperinsulinism of, 329
 p57^{KIP2} expression in β -cells in, 2763
 persistent hyperinsulinemic hypoglycemia of, focal, S182
 Inflammation markers, and glucose disorders, in elderly, 2384
 Injury, glomerular, early diabetic, SOD-1 protection against, in transgenic mice, 2114
Ins knockout mice, β -cell hyperplasia in, S150
 Insulin
 activity
 exercise training and, in rat, 2659
 GLP-1 effects on, in type 1 diabetes, 565
 regulation by calpains, 2013
 in skeletal muscle, with conjugated linoleic acid, 1149
 systemic versus portal delivery effects on, in pancreas transplantation, 1402
 TNF- α effects on, in human muscle, 1102
 autoantibodies
 induction by B9-23, in mice, 1274
 in NOD mice, 2451
 and brain glucose transport, 2203
 capillary recruitment by
 exercise training and, in rat, 2659
 in muscle, in hyperinsulinemia, 2682
 delivery of, systemic versus portal effects on insulin action and VLDL metabolism, in pancreas transplantation, 1402
 dysregulation in congenital hyperinsulinism, 322
 exocytosis of, calmodulin-Rab3A association and, 2029
 expression of
 β -cell-specific, S131
 glucose-regulated, and PDX-1 deficiency, in *P. obesus* type 2 diabetes, S138
 fasting, gene effects on, in familial combined hyperlipidemia, 2396
 and glycogen metabolism, 1872
 hepatic activity, in obese type 2 diabetes, 1363
 and hepatic glucose production, 1872
 and hepatic protein synthesis rates, in swine model, 947
 and hepatic proteoglycans, 2126
 in human yolk sac, 199
 K_{ATP} channel activation by, in β -cells, 2192
 low-dose, and hypoglycemia, in dog, 558
 mRNA levels, hyperglycemia and, in Zucker diabetic fatty rats, 2481
 p38 MAPK α and β activation by, and rat skeletal muscle contraction, 478
 PAI-1 signal transduction mediation by, in HepG2 cells, 1522
 PKC δ activation by, in proliferation, 255
 and plasma 8-hydroxyguanine levels in diabetic rats, 2837
 postprandial cephalic response, in humans, 1030
 postprandial hepatic clearance, β -cell mass decrease and, in minipig, 2001
 production by embryonic stem cells, 1691
 regulation of, model for, S178
 regulation of cholesterol metabolism by, 955
 regulation of gene expression by, in human skeletal muscle and adipose tissue, 1134
 regulation of glycogen synthesis by, in human muscle cells, 720
 regulation of mitochondrial and cytoplasmic protein synthetic rates by, 2652
 secretion of
 assessment of, model for, S178
 BL11282 and, in β -cells, 797
 CAPN10 UCSNP-43 polymorphism and, 2161
 during exercise, 1834
 free fatty acid effects on, 803
 in PPAR- γ Pro12A1a, 1143
 in GK rat islets, S108
 glucose-stimulated
 genes in, identification of, S134
 hormone-sensitive lipase role in, 1970
 model for, S164
 in HSL-deficient mice, 1970
 in hyperinsulinism of infancy, 329
 IRS-1 Gly972Arg and, 882
 after islet transplantation, 710
 nerve growth factor and, 1755
 p85 α variants and, 690
 in Pima Indians, 1828
 plasma leptin and, 348
 potentiation by efroxan, K_{ATP} channel-independent, 340
 PPAR- γ Ala¹² variant and, in type 2 diabetes, 891
 pulsatile
 β -cell mass decrease and, in minipig, 2001
 GLP-1 and, in type 2 diabetes, 776
 glucose metabolism and, 1785
 modulation by intrapancreatic ganglion neurons, 51
 sulfonyleurea and, in type 2 diabetes, 1778
 regulation by β -cell neuronal nNOS, 1311, 2177
 regulation by calpains, 2013
 rosiglitazone effects on, 2598
 stimulation by anti-CD38 autoantibodies, in human islets, 985
 swelling-induced, 992
 in type 2 diabetes, S169
 PPAR- γ Ala¹² variant and, 891
 UCP2 effects on, 803
 signaling in diabetic heart, in rat, 2709
 signaling in high fat-fed rat muscle, 1901
 signaling in skeletal muscle, in glucose-intolerant relatives with type 2 diabetes, 2770
 -stimulated endothelial function, in type 2 diabetic patients with ischemic heart disease, 2611
 -stimulated glucose transport, inhibition by indinavir, in skeletal muscle, 1397
 -stimulated glucose uptake, effects of chronic AICAR treatment on, in rat skeletal muscles, 12
 in vivo signaling, p85 α variants and, 691
 Insulin promoter factor-1, and β -cell development, S36
 Insulin receptor
 and β -cells, S146
 dephosphorylation, adipocytes, in rat, 83
 inhibition by Q¹²¹PC-1, 831
 Q¹²¹PC-1 interactions, 831
 sensitization by TLK16998, 824
 signaling in type 2 diabetic patient relatives, 2572
 small-molecule sensitizers, 824
 Insulin receptor activators, small molecule, 2323
 Insulin receptor substrate-1
 allelic variants in PCOS insulin resistance, 2164
 degradation of, trigger by phosphorylation, 24
 Gly972Arg polymorphism, and insulin secretion, 882
 tyrosine phosphorylation, in type 2 diabetic patient relatives, 2572
 Insulin receptor substrate-2, allelic variants in PCOS insulin resistance, 2164
 Insulin receptor substrate proteins
 and β -cell function, S140
 subcellular localization of, in mice, 1455
 Insulin receptor-deficiency, endocrine pancreas in, in mouse pups, S146
 Insulin resistance
 adiponectin levels in, in rhesus monkeys, 1126
 adipose tissue remodeling in, pioglitazone and, 1863
 amelioration by AJ-9677, in KK-A^y/Ta diabetic obese mouse, 113
 AMPK activation in, in rats, 1076
 apolipoprotein C1 protection against, in mice, 2779
 cardiomyocyte dysfunction with, in sucrose-fed rats, 1186
 cellular mechanism of, in nutritionally induced *P. obesus*, 584
 by ceramide, 2563
 dyslipidemia of, hepatic proteoglycans and, 2126
 endothelial, in type 2 diabetic patients with ischemic heart disease, 2611
 fatty acid uptake and metabolism in, in Zucker diabetic fatty rats, 1389
 fatty acid-induced, susceptibility to, in women, 1344
 free fatty acid-induced, prevention by thiazolidinedione, in male Wistar rats, 2316
 GH-induced, 1891
 free fatty acids and, 2301
 HDLs in, in apoA-II transgenic mice, 643
 high-fat diet-induced, in PPAR- α -null mice, 2809
 in high-salt diet-fed rats, 573
 hLPL overexpression and, in mouse skeletal muscle, 1064, 1512
 hyperglycemia-induced, insulin receptor dephosphorylation in, in rat adipocytes, 83
 indinavir and, 1397
 induction of
 by free fatty acids, in rats, 418
 by indinavir, 1378
 by nelfinavir, in 3T3-L1 adipocytes, 1425
 by overfeeding, 2786
 insulin-resistant sensitizers in, 2323
 intramyocellular lipid accumulation and, in rats, 123
 intramyocellular lipid and, 2337

- α -lipoic acid protection against, in rat L6 muscle cells, 404
 in liver IGF-I-knockout mice, 1110
 muscle, fatty acids and, 1344
 nonalcoholic fatty liver disease and, 1844
 P20 and, 1821
 PC-1 gene in, 1952
 PET dose response in, in skeletal muscle, 2069
 plasma FFAs and, 1612
 in polycystic ovary syndrome, IRS-1 and IRS-2 allelic variants in, 2164
 pubertal, 2444
 rescue by transgenic leptin, in mouse model, 1440, 1675
 resistance to exercise-induced glucose uptake in skeletal muscle with, in type 1 diabetes, 1371
 skeletal muscle, impaired glucose transport and phosphorylation interactions in, 2069
- Insulin sensitivity**
 antilipolytic, PPAR- γ_2 Pro12A1a and, 876
 of endogenous glucose production suppression, 1449
 and fat, in prepubertal children, 477
 free fatty acid effects on, in PPAR- γ_2 Pro12A1a, 1143
 gene effects on, in familial combined hyperlipidemia, 2396
 intramyocellular lipid content and, 2579
 oral glucose tolerance test minimal model index of, 150
 p85 α variants and, 690
 PPAR- α effects on, lipids and, in high fat-fed rats, 411
 in RII $\beta^{-/-}$ mice, 2555
- Insulin sensitization, thiazolidinedione mechanism of, 1083**
- Insulin therapy**
 short-term improvement of, effects on hepatic glycogen metabolism in type 1 diabetes, 392
 for type 2 diabetic patients with ischemic heart disease, 2611
- Insulin-like growth factor binding protein IGFBP-1, phosphorylation in IGFBP-1 transgenic mice, 32**
- Insulin-like growth factor I**
 gene polymorphism, 637
 inhibition of diabetic cardiomyopathy by, 1414
 liver IGF-I-knockout mice, insulin resistance in, 1110
 liver-derived, metabolic effects of, 1539
 proliferation of keratinocytes by, insulin activation of PKC δ in, 255
 signaling in diabetic retina by, 175
- Insulin-like growth factor**
 II/mannose-6-phosphate receptor, in diabetes-impaired nephrogenesis, 1069
- Insulinoma-associated tyrosine phosphatase-like protein IA-2**
 coding and promoter regions, 2406
 gene splicing, in pancreas and lymphoid organs, 895
 preparation for detection of autoreactive T-cells, in type 1 diabetes, 1749
- Insulinotropic polypeptide, glucose-dependent, postprandial levels, in type 2 diabetes, 609**
- Insulin-producing cells**
 AR42J cell differentiation into, neurogenin 3 in, S10
 Fas regulation by cytokines in, 1741
 proliferation of, inhibition by STAT5, S40
- Insulin-resistant sensitizers, in insulin resistance, 2323**
- Insulin-secreting cells**
 free ADP in, 291
 JNK activity in, 2721
 Interferon- γ , signaling in β -cells, 2744
 Interleukin-1, -induced islet cell death, 551
 Interleukin-1 β
 -induced β -cell apoptosis, imidazole protection against, S70
 -induced protein expression changes in rat islets, proteome analysis of, 1056
 JNK stimulation by, in insulin-secreting cells, 2721
- 1st International NOD Mouse T-cell Workshop report, 2459**
- Internet, online monitoring, of gene expression in β -cells, S15**
- Intramyocellular fat, plasma FFAs and, 1612**
- Intramyocellular lipids**
 and insulin resistance, 2337
 in rats, 123
 and insulin sensitivity, 2579
- Intrauterine growth retardation, type 2 diabetes with, in rat, 2279**
- IPF1/PDX1 deficiency, and β -cell dysfunction, in *P. obesus*, 1799**
- IRS-2 gene, in late-onset type 2 diabetes, 1949**
- Ischemic heart disease, type 2 diabetes with, endothelial insulin resistance in, 2611**
- Islet amyloid polypeptide**
 human hIAPP-transgenic mice, oophorectomy promotion of islet amyloid formation in, S184
 pro-IAPP processing in PC2-knockout mice, 534
- Islet cell antigen 512 (ICA512). see Insulinoma-associated tyrosine phosphatase-like protein**
- Islet duodenal homeobox-1, and GLP-1 induction of β -cell differentiation, 784**
- Islet-specific glucose-6-phosphatase catalytic subunit-related protein gene promoter, mouse, in situ footprinting of, 502**
- J**
- Japanese subjects**
 maturity-onset diabetes in, *NEUROG3* mutations and, 694
 with type 2 diabetes, Pax4 gene mutation in, 2864
- JNK. see c-Jun NH $_2$ -terminal kinase**
- K**
- Keratinocytes**
 glucose effects on, 1627
 IGF-I-induced proliferation of, insulin activation of PKC δ in, 255
- Kidney**
 fetal, diabetes-impaired, IGF-II/M6PR in, 1069
 glucose handling
 in humans, 747
 in hypoglycemia, 2087
 release, measurements of, 905
 structure of, antihypertensive therapy effects on, in type 1 diabetic subjects with albuminuria, 843
- Kidney-pancreas transplantation, effects on atherosclerotic risk factors, 496**
- Kinase insert domain-containing receptor, retinal expression of, induction by cyclic stretch and hypertension, 444**
- Kit, expression in β -cells and developing pancreas, 2021**
- KK-A y /Ta diabetic obese mouse model, insulin resistance amelioration by AJ-9677 in, 113**
- L**
- L6 cells, glucose transport in, PED/PEA-15 effects on, mediation by PKC- α , 1244**
- L6 myotubes, troglitazone-induced GLUT4 translocation in, 1093**
- Lactate, release per fat cell, in type 2 diabetic relatives, 2344**
- Lactate/monocarboxylate transporter, expression and distribution in islets, 361**
- Leptin**
 galanin interactions, 2666
 and hepatic gene expression, in obese mice, 2268
 mechanism of action, 733
 plasma levels, and insulin secretion, 348
 regulation of cholesterol metabolism by, 955
 regulatory effects of, H $_1$ -receptor disruption and, in mice, 385
 transgenic rescue of lipotrophic diabetes by, in mouse model, 1440, 1675
- Leptin receptor, LEPR-B-expressing obesity/diabetes phenotype of LEPR-null mice, transgenic rescue of, 425**
- Leptin receptor deficiency, transgenic complementation of, 425**
- Leptin resistance**
 central histamine infusion in obese mice with, 377
 induction by overfeeding, 2786
- Lesions**
 atherosclerotic, smooth muscle accumulation in, in diabetic subjects, 851
 glomerular, modulation by ACE inhibitors, in diabetic nephropathy, 2619
- Leucine, regulation of β -cell mTOR-signaling pathway translation initiation by, 353**
- Linoleic acid, conjugated, antidiabetic properties of, 1149**
- Lipid transfer protein, activities in type 1 diabetes, 652**
- Lipids**
 intramyocellular
 and insulin resistance, 2337
 in rats, 123
 and insulin sensitivity, 2579
- metabolism of**
 AICAR effects on, in rats, 1076
 glucose and, 1402
 G6Pase inhibition effects, 2591
 liver-derived IGF-I and, 1539
 regulation of, skeletal muscle lipolysis in, 1604
 thiazolidinedione effects on, 1158
- neutral, synthesis in β -cells, 315**
- peroxidation, inhibition of, wound healing stimulation by, in genetically diabetic mouse, 667**
- and PPAR- α effects on insulin sensitivity, in high fat-fed rats, 411**
- skeletal muscle**
 and muscle fiber type, in type 2 diabetes and obesity, 817
 single-fiber analysis of, 817
 storage of, enhancement by AGAT- α overexpression, in adipose tissue and adipose tissue, 233
- Lipotrophic diabetes, rescue by transgenic leptin, in mouse model, 1440, 1675**
- Lipogenesis, G6Pase inhibition effects on, 2591**
- α -Lipoic acid**

- glucose uptake stimulation by, 1464
protective effects against insulin resistance, in rat L6 muscle cells, 404
- Lipolysis**
alterations in, subcellular localization of IRS family proteins and, in mice, 1455
basal, increase by nelfinavir, in 3T3-L1 adipocytes, 1425
 β -cell, GLP-1 and, 56
HSL β gene polymorphism and, 2410
PPAR- γ_2 Pro12A1a and, 876
skeletal muscle, regulation of lipid oxidation by, 1604
- Lipoprotein lipase**
glycated LDL uptake mediation by, 1643
hyperinsulinemic clamp in transgenic mice, 2585
macrophage, regulation by fatty acids, 660
overexpression, insulin resistance and, in mouse skeletal muscle, 1064, 1512
- Lipoproteins**
high-density
effects in adiposity and insulin resistance, in apoA-II transgenic mice, 643
transcriptional regulation by glucose, 1850
low-density, glycated, cellular uptake mediation by lipoprotein lipase, 1643
- Lipotoxicity**
 β -cell, 315
in obesity, S118
glucose, 2105
- Liver**
gene expression in, leptin and, in obese mice, 2268
glucokinase activity, in type 2 diabetes, 1351
glucose production by, insulin effects on, 1872
glycogen metabolism by
stimulation by fructose, in humans, 1263
in type 1 diabetes, 392
hypoglycemia in, detection of, 399
IGF-I derived from, metabolic effects of, 1539
insulin activity, in obese type 2 diabetes, 1363
- Liver disease, nonalcoholic fatty, 1844**
- Liver IGF-I-knockout mice, insulin resistance in, 1110**
- Liver proteins, synthesis rates, insulin effects on, in swine model, 947**
- Liver proteoglycans**
fatty acids and, 2126
insulin and, 2126
- Low-density lipoprotein, glycated, cellular uptake mediation by lipoprotein lipase, 1643**
- Lymphocytes, autoaggressive, protection from, in transgenic mice, 2700**
- Lymphoid organs, IA-2 gene splicing in, 895**
- M**
- Macrophages**
cholesterol ester metabolism in, regulation by insulin and leptin, 955
glycated LDL uptake in, mediation by lipoprotein lipase, 1643
lipoprotein lipase in, regulation by fatty acids, 660
- Magnesium-sensitive protein phosphatase, acetyl-CoA carboxylase activation by, in β -cells, 1580**
- Magnetic resonance imaging, functional study of acute hypoglycemia effects on brain, 1618**
- Maternal diabetes, altered nephrogenesis due to, IGF-II/M6PR in, 1069**
- Matrix metalloproteinase 2**
effects in adipose differentiation, 2080
production by adipocyte, 2080
- Matrix metalloproteinase 9**
effects in adipose differentiation, 2080
production by adipocyte, 2080
- Maturity-onset diabetes, *NEUROG3* mutations and, in Japanese subjects, 694**
- Meal ingestion**
cephalic insulin response to, in humans, 1030
initiation of, preprandial plasma ghrelin surges and, 1714
- Melanocortins, mechanism of action, 733**
- Men**
with type 1 diabetes, 18 F-FDG uptake at hypoglycemia in, 2329
type 2 diabetes risk among, drinking patterns and, 2390
- Menopause, in type 1 diabetic women, 1857**
- Mesangial cells**
hexosamines and fibronectin synthesis in, 2355
high glucose-enhanced ET-1 activation of ERK1/2 and α 1(IV) collagen in, 2376
- Metabolic rate, cerulenin effects on, 733**
- Metabolic syndrome, nonalcoholic fatty liver disease in, 1844**
- Metabolism**
and β -cell function and turnover, S84
and functional β -cell restoration after islet allotransplantation in type 1 diabetes, 277
- Metallothionein, and streptozotocin diabetes, 2040**
- Microalbuminuria, onset in type 1 diabetes, 2842**
- Microencapsulated islets, survival in NOD mice, 1698**
- Microthromboses, in diabetic retinopathy, 1432**
- Microvascular dilation, coronary, in type 2 diabetes, 1180**
- MIN6 cells, tetracycline-inducible (Tet-On) gene expression in, S133**
- Minipig, β -cell mass decrease in, 2001**
- Mitochondria**
protein synthesis, regulation by insulin, 2652
p70 s6k regulation, 353
superoxide overproduction by hyperglycemia, 1491
- Mitogen-activated protein kinase p38**
glucose uptake regulation by, 1464
phosphorylation downstream of Bax-caspase-3, endothelial apoptosis and, 1472
in RAGE-mediated NF- κ B activation, 1495
p44/p42, in RAGE-mediated NF- κ B activation, 1495
- Mitogen-activated protein kinase α and β , p38, activation by insulin, and rat skeletal muscle contraction, 478**
- Molecular aspects**
of pancreatic development, S5
regulation of Fas expression in β -cells, S83
- Monocarboxylate transporter, expression and distribution in islets, 361**
- Monoclonal antibodies, hamster anti-murine CD154 mAb MR1, chronic, islet graft survival prolongation by, in NOD mice, 270**
- Monounsaturated fatty acids, effects on β -cell turnover and function, 69**
- Motor nerve conduction velocity, antioxidant treatment and, 1927**
- Mouse studies**
apoA-II transgenic mice, 643
apolipoprotein C1 protection against obesity and insulin resistance, 2779
 β -cell mass in, in vivo measurement of, 2231
 β -cell-deficient mice, diabetogenic T cells in, 763
 β -cell-deficient NOD mice, diabetogenic T cells in, 763
C57BL/6J mice, diabetic embryopathy in, 1193
chromosome 18 association with autoimmunity, 184
clonal α cells, α TC6 cells, exocytosis of l-glutamate by, 1012
db/db mice, GLUT4 overexpression effects in, 593
diabetic mice
phenotypic correction by adenoviral glucokinase expression, 2287
SREBP-1c and glucose homeostasis in, 2425
wound healing stimulation by inhibition of lipid peroxidation in, 667
GK gene locus transgenic mice, resistance to obesity-induced type 2 diabetes in, 622
HGF effects on islet function and transplantation outcome, 2752
hLAPP-transgenic mice, oophorectomy promotion of islet amyloid formation in, S184
HSL-deficient mice, insulin secretion in, 1970
IGFBP-1 transgenic mice, IGFBP-1 phosphorylation in, 32
IGRP gene promoter in situ footprinting, 502
Ins knockout mice, β -cell hyperplasia in, S150
insulin autoantibody induction by B9-23, 1274
insulin receptor-deficient pups, endocrine pancreas in, S146
IRS family proteins in, subcellular localization of, 1455
KK-A y /Ta diabetic obese mouse model, insulin resistance amelioration by AJ-9677 in, 113
KK/Ta mouse model, susceptibility loci contributing to type 2 diabetes in, 1943
LEPR-null mice, LEPR-B-expressing obesity/diabetes phenotype of, transgenic rescue of, 425
leptin regulatory effects in, H $_1$ -receptor disruption and, 385
leptin-resistant obese mice, central histamine infusion in, 377
lipotrophic diabetes model, rescue by transgenic leptin, 1440, 1675
lipoprotein lipase-transgenic mice, hyperinsulinemic clamp in, 2585
liver IGF-I-knockout mice, insulin resistance in, 1110
MCKhLPL mice, insulin resistance in, 1064, 1512
NOD mice
autoantibodies in, 2451
diabetes in, decrease by adenovirus genes, 980

- Idd10* and *Idd18* loci mapping by genetic interaction in, 2633
- Idd5.1* mapping for autoimmune diabetes in, 2874
- islet graft survival prolongation by CD40-CD154 blockade in, 270
- microencapsulated islet survival in, 1698
- NKT cell deficiency in, 2691
- oral wound healing in, 2100
- phogrin T-cell epitopes in, 1729
- T-cell expansion in, 1992
- T-cell Workshops report, 2459
- NOD mice, β -cell-deficient, diabetogenic T cells in, 763
- obese mice, leptin and hepatic gene expression in, 2268
- PC2-knockout mice, pro-LAPP processing in, 534
- PPAR- α -null mice, and high-fat diet, 2809
- RIP $\beta^{-/-}$ mice, insulin sensitivity in, 2555
- transgenic mice
- cell surface GLUT4 in, 593
 - protection from autoaggressive lymphocytes, 2700
 - reversible β -cell autoimmunity and hyperplasia in, 2260
 - SOD-1 protection against early diabetic glomerular injury in, 2114
- MR1, chronic, islet graft survival prolongation by, in NOD mice, 270
- Mucosal antigen, diabetogenic CTL priming by, 771
- Muscle(s). *see also* Skeletal muscle; Smooth muscle
- AMPK activation in, in type 2 diabetes, 921
 - gene expression in, nonesterified fatty acids and, in rats, 601
 - GFAT-1 expression in, selective, 2419
 - GLUT4 content, effects of oral creatine supplementation on, in humans, 18
 - glycogen synthesis in, regulation by glucose, glycogen, and insulin, in human cells, 720
 - insulin activity in, TNF- α effects on, in human cells, 1102
 - insulin capillary recruitment in, in hyperinsulinemia, 2682
 - insulin resistance in
 - fatty acid uptake and metabolism with, in Zucker diabetic fatty rats, 1389
 - fatty acids and, 1344
 - α -lipoic acid protection against, in rat L6 cells, 404
 - insulin signaling in, in high fat-fed rats, 1901
 - lipids, and PPAR- α effects on insulin sensitivity, in high fat-fed rats, 411
 - triglyceride content, in lipoprotein-lipase transgenic mice, 2585
- Muscle carnitine palmitoyltransferase-1, inhibition of, promotion of intramyocellular lipid accumulation and insulin resistance by, in rats, 123
- Muscle fibers
- slow, GLUT4 in, in type 2 diabetes, 1324
 - types of, skeletal muscle lipid content and oxidative enzyme activity and, in type 2 diabetes and obesity, 817
- Muscle-protein breakdown, inhibition by growth hormone, 96
- Mutations
- β -cell gene, pathophysiology of, S101
 - β -cell transcription factors, S94
 - CART gene, in obese children, 2157
 - diabetes-associated *ACVR2B* mutations, in French patients, 1219
 - DRD2 gene Ser311Cys, and energy expenditure, 901
 - glucokinase, pathophysiology of, S101
 - HNF-1 α
 - aminoaciduria with, 2047
 - pathophysiology of, S101
 - missense Pax4 gene, in type 2 diabetes in Japanese, 2864
 - NEUROG3*, and maturity-onset diabetes in Japanese subjects, 694
 - point *CTLA4* gene, in West African type 1 diabetes patients, 2169
 - sulfonylurea receptor, congenital hyperinsulinism due to, insulin dysregulation in, 322
- Myoblasts, glycogen synthesis in, regulation by glucose, glycogen, and insulin, in human cells, 720
- Myocardial infarction, risk for, IGF-I gene polymorphism and, 637
- Myocytes, cell death, hyperglycemia and p53 and, 2363
- Myofibrils, degeneration induction by glucose and palmitic acid, in rat cardiomyocytes, 2105
- Myotubes, L6, troglitazone-induced GLUT4 translocation in, 1093
- N**
- Na-Pi cotransporter, expression during AR42J cell differentiation, S39
 - Natural killer T-cell deficiency, in NOD mice, 2691
 - Necrosis, IL-1-induced, of islet cells, 551
 - Nelfinavir, adipocyte metabolism alteration by, 1425
 - Neonates, GLP-1 treatment in, β -cell neogenesis by, in rats, 1562
 - Nephrogenesis, diabetes-impaired, IGF-II/M6PR in, 1069
 - Nephropathy, diabetic
 - candidate gene screening in, 1214
 - glomerular lesions in, modulation by ACE inhibitors, 2619
 - Nerve growth factor, effects on insulin secretion and barium current, 1755
 - Nestin-positive stem cells, differentiation of, 521
 - Neural cell adhesion molecule, sialylated, S125
 - Neurogenin 3
 - in AR42J cell differentiation, S10
 - human *neurogenin3* promoter, 928, 1512, 1675
 - NEUROG3* mutations, and maturity-onset diabetes in Japanese subjects, 694
 - regulation of, 928, 1512, 1675
 - Neuropathy
 - autonomic, and parental diabetes, Fredericia Study, 630
 - diabetic, vascular dysfunction in, 1927
 - Neuropeptide Y
 - hypothalamic, ghrelin effects on, in rat, 2438
 - overexpression, and obesity, 1206
 - secretion of, modulation by galanin, 2666
 - Neuropeptide Y/Y1 receptor, hypothalamic pathway, activation by ghrelin, 227
 - Nicorandil
 - action on K_{ATP} channels, 2253
 - sulfonylurea interactions, 2253
 - Niddm1i* gene locus, stimulus secretion coupling to, in GK rats, 2737
 - Nitric oxide
 - glucose uptake stimulation by, in rat skeletal muscle, 241
 - metabolism during cardiac surgery, diabetes and, 2603
 - Nitric oxide synthase, β -cell neuronal nNOS, insulin secretion regulation by, 1311, 2177
 - NN2211, weight loss therapy with, 2530
 - Nuclear factor- κ B
 - activation of
 - dsRNA-induced, in islets, 283
 - RAGE-mediated p38 MAPK-dependent, 1495
 - sustained, diabetes-associated, 2792
 - and β -cell apoptosis, 2219
 - and Fas regulation by cytokines, 1741
 - Nutrients, PPAR γ gene-nutrient interactions, 686
- O**
- ob* gene, effects on endocrine cell proliferation and differentiation in transplanted human islets, 301
 - Obesity
 - adipose tissue remodeling in, pioglitazone and, 1863
 - adrenoceptor gene variants and, in Caucasian women, 91
 - apolipoprotein C1 protection against, in mice, 2779
 - β -cell lipotoxicity in, S118
 - CART gene mutations in children with, 2157
 - central histamine infusion in leptin-resistant mice with, 377
 - chromosome 18p11 loci for type 2 diabetes with, genome scan for, 675, 1512
 - combined dyslipidemia in, normalization by ezetimibe, in hyperinsulinemic hamsters, 1330
 - endothelial dysfunction induction in, 159
 - gene expression profiling of omental fat in, 2822
 - ghrelin levels in, in humans, 707
 - ghrelin-induced, in rats, 2540
 - glucose metabolism in Zucker rats with, AICAR effects on, 1076
 - GLUT4 expression in, 1324
 - hepatic insulin activity in type 2 diabetes with, 1363
 - leptin and hepatic gene expression in, in mice, 2268
 - lipid metabolism in Zucker rats with, AICAR effects on, 1076
 - neuropeptide Y overexpression and, 1206
 - resistance to type 2 diabetes with, in GK gene locus transgenic mice, 622
 - resistin/Fizz3 expression and, 2199
 - skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in, 817
 - SURI sequence variants and, 697
 - Obesity/diabetes phenotype, LEPR-B-expressing, of LEPR-null mice, transgenic rescue of, 425
 - Oligonucleotide arrays, high-density, identification of novel cytokine-induced genes in β -cells by, 909
 - Omental fat, gene expression profiling of, 2822
 - Online monitoring, of gene expression in β -cells, S15
 - Oophorectomy, promotion of islet amyloid formation by, in hLAPP-transgenic mice, S184
 - Oral glucose tolerance test, 2-h criteria, type 1 diabetes by, 470
 - Oral glucose tolerance test minimal model analysis, of β -cell function and insulin sensitivity, 150

- Oral wound healing, in NOD mice, 2100
- Orexin neurons, activation by hypoglycemia, 105
- Orexin-A, glucose-sensitive neuron excitement by, in rat hypothalamus, 2431
- Orexin-B, hypothalamic levels, increase by hypoglycemia, 105
- Osteopontin, stimulation by hypoxia, 1482
- Overfeeding, leptin and insulin resistance induction by, 2786
- Overstimulation, and β -cell function, S122
- Oxidative enzymes, skeletal muscle, and muscle fiber type, in type 2 diabetes and obesity, 817
- Oxidative stress
- AngII-mediated, inhibition by IGF-1 overexpression, 1414
 - endothelial dysfunction induction by, in obesity, 159
 - insulin resistance induced by, α -lipoic acid protection against, in rat L6 muscle cells, 404
- Oxygen tension, in transplanted rat islets, 489
- P**
- P20, and insulin resistance, 1821
- p38 mitogen-activated protein kinase
- glucose uptake regulation by, 1464
 - phosphorylation downstream of
 - Bax-caspase-3, endothelial apoptosis and, 1472
 - in RAGE-mediated NF- κ B activation, 1495
- p38 mitogen-activated protein kinase α and β , activation by insulin, and rat skeletal muscle contraction, 478
- p44/p42 mitogen-activated protein kinase, in RAGE-mediated NF- κ B activation, 1495
- p53, activation by hyperglycemia, 2363
- p53-related genes, activation by hyperglycemia, 2363
- p57^{KIP2}, expression in β -cells, 2763
- p70 S6 kinase, mitochondrial regulation of, 353
- p85 α , variants, and insulin signaling in vivo, 691
- Palmitate
- glycogen inhibition by, 2210
 - protein kinase B/Akt inhibition by, 2210
- Palmitic acid
- apoptosis modulation by, in rat cardiomyocytes, 2105
 - myofibril degeneration induction by, in rat cardiomyocytes, 2105
- Pancreas
- development of
 - biology of, S5
 - Kit* expression during, 2021 - embryonic cell expansion by EGF, 1571
 - endocrine
 - cell survival, ATP-sensitive K⁺ channels in, S48
 - differentiation of
 - ATP-sensitive K⁺ channels in, S48
 - in pig-to-mouse model, 962 - fetal, ontogeny of, 962
 - in insulin receptor-deficient mouse pups, S146
 - nestin-positive stem cell differentiation into, from adult islets, 521
 - plasticity of, S30 - exocrine
 - monocarboxylate transporter expression and distribution in, 361
 - nestin-positive stem cell differentiation into, from adult islets, 521
- PDX-1 misexpression in, glucose tolerance and acinar dysmorphogenesis by, 1553
- IA-2 gene splicing in, 895
- insulin secretory response, rosiglitazone effects on, 2598
- precursor cells, novel line for β -cell differentiation study, S42
- response to mild hypoglycemia, 2487
- Pancreas transplantation. *see also*
- Kidney-pancreas transplantation
 - insulin delivery in, systemic versus portal effects on insulin action and VLDL metabolism, 1402
- Pancreatectomy, for chronic pancreatitis, prevention of diabetes by autoislet transplantation after, 47
- Pancreatic β -cells. *see* β -cells
- Pancreatic biopsy, in type 1 diabetes, 1269
- Pancreatic duodenal homeobox-1
- gene expression
 - β -cell-specific, S131
 - glucose tolerance and acinar dysmorphogenesis by, in exocrine pancreas, 1553
 - regulatory elements in, S37
 - shuttling in β -cells, 2244
- Pancreatic duodenal homeobox-1 deficiency and β -cell dysfunction, in *P. obesus*, 1799
- and glucose-regulated insulin gene expression, in *P. obesus* type 2 diabetes, S138
- Pancreatic islet cells. *see also* β -cells
- adeno-associated virus transduction of, 515
 - adenylate cyclase activity in, in rat, 2505
 - allogeneic, stable, reversal of
 - streptozotocin-induced diabetes with, in type 1 model, 1227 - allorejection of, protection against, by barium-alginate membrane, 1698
 - allotransplantation in type 1 diabetes, 277
 - amyloidosis of
 - characteristics of, 2514
 - promotion by oophorectomy, in hLAPP-transgenic mice, S184 - antibodies, GAD65 autoantibodies in relatives with, 1735
 - apoptosis in, induction by high glucose, in human cells, 1290
 - clusters, cytoplasmic Ca²⁺ in, measurements of, 540
 - congenic, phenotyping of, in GK rats, 2737
 - cytotoxic damage to, prevention by TIMP-1, 1047
 - death of, IL-1-induced, 551
 - development of, HNF-1 α and, 2472
 - differentiation of, ATP-sensitive K⁺ channels in, S48
 - dsRNA-induced activation of NF- κ B in, 283
 - Fas receptor upregulation by glucose in, 1683
 - free fatty acid cytotoxicity in, 1771
 - function of
 - HGF effects on, in mice, 2752
 - pituitary adenylate cyclase-activating peptide and, 1959 - gene expression in, in suckling rats, 2053
 - glucose induction of hormone-sensitive lipase in, in rat islets, 2225
 - glucose metabolism and pulsatile insulin release from, 1785
 - glycerol-stimulated proinsulin biosynthesis in, in rat, 1791
 - IL-1 β -induced protein expression changes in, proteomic analysis of, in rats, 1056
 - IL-1-induced necrosis and apoptosis of, 551
 - insulin release in
 - in GK rat, S108
 - stimulation by human anti-CD38 autoantibodies, 985 - metabolism of, HNF-1 α and, 2472
 - microencapsulated, survival in NOD mice, 1698
 - monocarboxylate transporter expression and distribution in, 361
 - nestin-positive stem cells from, differentiation of, 521
 - p57^{KIP2} expression in, 2763
 - plasticity of, S30
 - pulsatile insulin release from, glucose metabolism and, 1785
 - pyruvate dehydrogenase kinase isoform expression in, in rat, 2729
 - stimulus-secretion coupling in, in *P. obesus*, 308
 - total mass, 1763
 - transduction with fusion proteins, 1706
 - transplantation
 - autoantibody response to, in type 1 diabetes, 2464
 - endocrine cell proliferation and differentiation in, 301
 - HGF effects on, in mice, 2752
 - outcomes and insulin secretion after, 710
 - oxygen tension in, rat, 489
 - in type 1 diabetes, 277
 - triacylglycerol content, hyperglycemia and, in Zucker diabetic fatty rats, 2481
 - triglyceride content, free fatty acid cytotoxicity and, 1771
 - in type 2 diabetes, S1
 - volume, volume-weighted mean, 1763
- Pancreatic islet grafts
- function of, heme oxygenase-1 induction and, 1983
 - survival prolongation by CD40-CD154 blockade, in NOD mice, 270
- Pancreatitis, chronic, pancreatectomy for, prevention of diabetes by autoislet transplantation after, 47
- Parental diabetes, autonomic neuropathy and, Fredericia Study, 630
- Parent-of-origin effects, genome-wide scan for, 2850
- Pax4 gene, missense mutation in type 2 diabetes in Japanese, 2864
- PC-1
- in insulin resistance, 1952
 - Q allele variant (GLN¹²¹) Q¹²¹PC-1, insulin receptor interactions and inhibition by, 831
- PC2. *see* Prohormone convertase enzyme 2
- PDX-1. *see* Pancreatic duodenal homeobox-1
- PED/PEA-15, glucose transport effects, mediation by PKC- α , in L6 skeletal muscle cells, 1244
- Peripheral tissue insulin resistance, fatty acid-induced, susceptibility to, in women, 1344
- Peroxisome proliferator-activated receptor(s), in macrophage LPL regulation by fatty acids, 660
- Peroxisome proliferator-activated receptor- α and high-fat diet, 2809
- and insulin sensitivity, in high fat-fed rats, 411
- Peroxisome proliferator-activated receptor- χ , activity, resistin/Fizz3 expression and, 2199
- Peroxisome proliferator-activated receptor- χ 2 gene, and weight loss, 2172

- Peroxisome proliferator-activated receptor- γ ligands, and adiponectin expression, 2094
- Peroxisome proliferator-activated receptor- γ Ala¹² variant, association with diabetes resistance, 891
- gene-nutrient interactions, 686
- Peroxisome proliferator-activated receptor- γ_{25} Pro12Ala variant
- association with type 2 diabetes and trait differences, 886
- free fatty acid effects on insulin secretion and sensitivity in, 1143
- and lipolysis, 876
- Phenotype
- of congenic islets, in GK rats, 2737
- correction of diabetes by, in mice, 2287
- of rebred Cohen diabetic rat, 2521
- Phogrin T-cell epitopes, in NOD mice, 1729
- Phosphatidylinositol 3-kinase activity, subcellular localization of IRS family proteins and, in mice, 1455
- rosiglitazone effects on pancreatic insulin secretory response and, 2598
- Phosphoenolpyruvate carboxykinase, gene expression reduction by GSK-3 inhibitors, 937
- Phosphoinositide 3-kinase, p85 α subunit, variants, and insulin signaling in vivo, 691
- Phosphoprotein P20, and insulin resistance, 1821
- Phosphorylation
- IGFBP-1, in IGFBP-1 transgenic mice, 32
- impaired glucose transport interactions, in insulin resistance, 2069
- serine/threonine, IRS-1 degradation trigger by, 24
- Pigment epithelium-derived factor, loss in angiogenic eye disease, 2641
- Pigs. *see* Swine studies
- Pima Indians
- gamma globulin levels and type 2 diabetes in, 1598
- genome-wide scan for parent-of-origin effects in, 2850
- insulin secretion in, 1828
- Pioglitazone
- and adipose tissue remodeling, 1863
- insulin-sensitizing mechanism of, 1083
- Pituitary adenylate cyclase-activating peptide, and islet function, 1959
- Plasma adiponectin, PPAR γ ligands and, 2094
- Plasma apolipoprotein B-48 lipoproteins, modulation by hyperinsulinism, 462
- Plasma free fatty acids
- effects on intramyocellular fat content, 1612
- in subjects at high-risk for type 2 diabetes, 2548
- Plasma ghrelin, preprandial surges in, 1714
- Plasma glucose
- α -cell responses to, in dog, 367
- β -cell responses to, in dog, 367
- decrease by tramadol, in diabetic rats, 2815
- Plasma 8-hydroxyguanine, in diabetic rat, 2837
- Plasma leptin, and insulin secretion, 348
- Plasma membrane glycation, endothelial, in diabetes, 1666
- Plasmalemma-associated proteins, endothelial, in diabetes, 1666
- Plasminogen activator inhibitor type 1, insulin-mediated signal transduction, in HepG2, 1522
- Plasticity
- endocrine pancreas, S30
- islet, S30
- Platelets, induction by hyperglycemia, 1491
- Polycystic ovary syndrome, insulin resistance in, IRS-1 and IRS-2 allelic variants in, 2164
- Polymorphic studies, in diabetes, 2646
- Polyreactive type 1 diabetes, Fas function in, 483
- Portal vein
- glucosensor locus, confirmation of, 399
- insulin delivery, effects on insulin action and VLDL metabolism, 1402
- Positron emission tomography
- dose response in insulin-resistant skeletal muscle, 2069
- FDG-PET, in counter-regulatory failure, 2329
- Potassium channels, ATP-sensitive activation by insulin, in β -cells, 2192
- in endocrine pancreas cell survival and differentiation, S48
- nicorandil action on, 2253
- Preadipocytes, differentional inhibition by indinavir, 1378
- Pro12Ala gene, and weight loss, 2172
- Prohormone convertase enzyme 2, in mice pro-IAPP processing, 534
- Proinsulin
- glycerol-stimulated biosynthesis, in rat islets, 1791
- preparation for detection of autoreactive T-cells, in type 1 diabetes, 1749
- Pro-islet amyloid polypeptide, processing in PC2-knockout mice, 534
- Prolactin, insulin-producing cell proliferation induced by, inhibition by STAT5, S40
- Protein
- metabolism in cystic fibrosis, 1336
- mitochondrial and cytoplasmic synthesis of, regulation by insulin, 2652
- muscle-protein breakdown inhibition by growth hormone, 96
- retaining effects of growth hormone during fasting, 96
- Protein kinase, dsRNA-dependent, and dsRNA-induced activation of NF- κ B in islets, 283
- Protein kinase A, RI $\beta^{-/-}$ mice, insulin sensitivity in, 2555
- Protein kinase B, inhibition by p85 α variants, 691
- Protein kinase B/Akt, inhibition by palmitate, 2210
- Protein kinase C
- angiotensin II-dependent translocation, 1918
- in high glucose-enhanced ET-1 activation of ERK1/2 and α 1(IV) collagen, in mesangial cells, 2376
- Protein kinase C- α , PKC- ζ inhibition by, in L6 skeletal muscle cells, 1244
- Protein kinase C- δ , activation by insulin, in proliferation, 255
- Protein kinase C- ϵ , overexpression in skeletal muscle, before diabetes, 584
- Protein kinase C- ζ and GLP-1-induced β -cell growth, 2237
- inhibition by PKC- α , in L6 skeletal muscle cells, 1244
- Protein phosphatase, glutamate- and magnesium-sensitive, acetyl-CoA carboxylase activation by, in β -cells, 1580
- Proteoglycans, hepatic fatty acids and, 2126
- insulin and, 2126
- Proteome analysis, of IL-1 β -induced protein expression changes in rat islets, 1056
- Psammomys obesus*
- β -cell dysfunction in, 1799
- β -cell glucotoxicity in, S113
- islet stimulus-secretion coupling in, 308
- nutritionally induced insulin resistance in, cellular mechanism of, 584
- PDX-1 deficiency in
- β -cell dysfunction and, 1799
- glucose-regulated insulin gene expression and, S138
- Pubertal insulin resistance, 2444
- Pyruvate dehydrogenase kinase, isoform expression in islets, in rat, 2729
- Q**
- QTc dispersion, and diurnal BP variations, in diabetes, 837
- Québec Family Study, genome-wide scan for abdominal fat in, 614
- R**
- Rab3A, association with calmodulin, 2029
- RAGE. *see* Receptor for advanced glycation end-products
- Rapamycin, mammalian target mTOR of, β -cell translation initiation through, regulation by leucine, 353
- Rat studies. *see also* *Psammomys obesus*
- BB rat thymocytes, 972, 2414
- β -cell apoptosis in, Bcl-2 and Bax- Ω downregulation and, S82
- blastocyst Bcl-2, 143
- cardiomyocyte apoptosis modulation by glucose and palmitic acid, 2105
- chromosome 18 association with autoimmunity, 184
- chronic AICAR effects on skeletal muscle insulin-stimulated glucose uptake and GLUT4 translocation, 12
- diabetic rats
- cardiac β -adrenoceptor expression in, 455
- cardiac insulin signaling in, 2709
- combination benzylamine and vanadate treatment of, 2061
- plasma 8-hydroxyguanine levels in, 2837
- tramadol plasma glucose-lowering effects in, 2815
- exercise training and insulin action, 2659
- exercise-stimulated glucose turnover, glucosamine and, 139
- ghrelin effects on hypothalamus, 2438
- ghrelin-induced hyperphagia and obesity in, 2540
- GK rats
- β -cell development in, S84
- β -cell function and viability in, S89
- insulin release in islets in, S108
- phenotyping of congenic islets in, 2737
- gluconeogenesis in small intestine, 740
- glucose induction of hormone-sensitive lipase in islets, 2225
- glucose uptake in skeletal muscle, NO-stimulated, 241
- GLUT4 translocation by troglitazone in, in adipocytes, 2296
- glycerol-stimulated proinsulin biosynthesis in islets, 1791
- high fat-fed rats
- insulin signaling in muscle in, 1901
- lipids and PPAR- α effects on insulin sensitivity in, 411
- high free fatty acid availability in, energy fuel channeling toward fat vs muscle during, 601
- high-salt diet-fed rats, insulin resistance in, 573
- hypertensive rats, muscle glucose transport in, 2148

- hypoglycemia effects on adrenal sympathetic activity, 1119
 insulin p38 MAPK α and β activation and skeletal muscle, 478
 insulin receptor dephosphorylation in adipocytes, 83
 insulin resistance induction by free fatty acids, 418
 insulin-resistant L6 muscle cells, α -lipoic acid protection against, 404
 insulin-resistant rats
 AMPK activation in, 1076
 intramyocellular lipid accumulation and, 123
 male Wistar rats, thiazolidinedione prevention of FFA-induced insulin resistance in, 2316
 myofibril degeneration by glucose and palmitic acid cardiomyocytes, 2105
 newborn rats, β -cell neogenesis by GLP-1 treatment in, 1562
 nonesterified fatty acids and gene expression in fat and muscle, 601
 orexin A excitement of GSN in, 2431
 pancreatic islets
 adenylyl cyclase activity in, 2505
 IL-1 β -induced protein expression changes in, proteome analysis of, 1056
 pyruvate dehydrogenase kinase isoform expression in, 2729
 transplanted, oxygen tension in, 489
 rebred Cohen diabetic rat, phenotype of, 2521
 suckling rats, islet gene expression in, 2053
 sucrose-fed rats, cardiomyocyte dysfunction with insulin resistance in, 1186
 thiazolidinedione action in skeletal muscle, 2309
 type 2 diabetic rats, intrauterine growth retardation and, 2279
 Zucker diabetic fatty rats
 AICAR effects on glucose and lipid metabolism in, 1076
 β -cell mass dynamics in, 1021
 β -cell transcription defect in, 63
 fatty acid uptake and metabolism in insulin-resistant muscle of, 1389
 GIP receptor expression in, 1004
 hyperglycemia and increased islet TAG content, 2481
 tungstate effects in, 131
 Receptor for advanced glycation end-products chromosome 6 *vs* chromosome 3 5' regulatory region variation, 2646
 functional gene promoter polymorphisms, 1505
 p38 MAPK-dependent NF- κ B activation mediated by, 1495
 Relatives. *see* Families
 Research, ADA-funded, year 2 status, 1222
 Resistin/Fizz3, expression in humans, 2199
 Retina
 angiopoietin-2 induction by AII in, in bovine endothelial cells, 867
 metabolism in diabetes and galactosemia, 1938
 VEGF-R2 expression induction by cyclic stretch and hypertension, 444
 Retinopathy, diabetic
 antioxidant effects on, 1938
 functional RAGE promoter polymorphisms and, 1505
 IGF-I signaling in, 175
 inhibition by aminoguanidine and aspirin, 1636
 microthromboses in, 1432
 Rhesus monkeys, insulin-resistant, adiponectin levels in, 1126
 RNA, double-stranded, NF- κ B activation in islets by, 283
 Rosiglitazone
 effects on β -cell mass dynamics in Zucker diabetic fatty rats, 1021
 effects on pancreatic insulin secretory response, 2598
 S
 Salt, insulin resistance in high-salt diet-fed rats, 573
 Sand rat. *see* *Psammomys obesus*
 Sarcoplasmic reticulum dysfunction, in diabetic heart, 2133
 Saturated fatty acids, effects on β -cell turnover and function, 69
 Sciatic nerve, epineurial arterioles, antioxidant treatment and, 1927
 Second International Immunology of Diabetes Society Workshop for Standardization of T-cell Assays in Type 1 Diabetes, phase II report, 1749
 Semicarbazide-sensitive amine oxidase substrates, antidiabetic effects in diabetic rats, 2061
 Serine/threonine phosphorylation, IRS-1 degradation trigger by, 24
 Serum, from type 1 diabetes patients, effects on cerebellar granule cells, S77
 Sex differences, diet-induced type 2 diabetes with, rebred Cohen rat model of, 2521
 Sex ratio, fetal, in C57BL/6J mice, 1193
 Siblings. *see also* Families
 of type 1 diabetic children, autoantibody seroconversions in, 2625
 Signal transducers and activators of transcription STAT5, inhibition of insulin-producing cell proliferation by, S40
 Single nucleotide polymorphisms (SNPs)
 CAPN10 UCSNP-43, and insulin secretion, 2161
 of PC-1 gene, in insulin resistance, 1952
 Skeletal muscle
 AGAT- α overexpression effects in, 233
 contraction of, insulin p38 MAPK α and β activation and, in rat, 478
 glucose transport in
 in hypertensive rats, 2148
 inhibition by indinavir, 1397
 PED/PEA-15 effects on, mediation by PKC- α , in L6 cells, 1244
 glucose uptake in
 insulin-stimulated, chronic AICAR treatment and, in rat, 12
 NO-stimulated, in rat, 241
 glycogen synthase content, *GYS1 XbaI* gene polymorphism and, 195
 glycogen synthase kinase-3 regulation in, 265
 hexokinase isozymes in, in humans, 1253
 hLPL overexpression in, insulin resistance and, in mouse, 1064, 1512
 insulin activity in
 with conjugated linoleic acid, 1149
 gene expression regulation, 1134
 glucose uptake and GLUT4 translocation stimulation, chronic AICAR treatment and, in rat, 12
 insulin resistance in, intramyocellular lipid and, 2337
 insulin signaling in
 in glucose-intolerant relatives with type 2 diabetes, 2770
 in high fat-fed rats, 1901
 insulin-resistant
 impaired glucose transport and phosphorylation interactions in, 2069
 PET dose response in, 2069
 resistance to exercise-induced glucose uptake, in type 1 diabetes, 1371
 lipid content, in type 2 diabetes and obesity, 817
 lipolysis, regulation of lipid oxidation by, 1604
 oxidative enzyme activity, in type 2 diabetes and obesity, 817
 PKC ϵ overexpression in, before diabetes, 584
 single-fiber analysis of lipid and oxidative enzymes, 817
 thiazolidinedione action in, in rat, 2309
 UCP3 content, in type 2 diabetes, 2870
 Skin keratinocytes
 glucose effects on, 1627
 IGF-1-induced proliferation of, insulin activation of PKC δ in, 255
 Slow muscle fibers, GLUT4 in, in type 2 diabetes, 1324
 Small intestine, gluconeogenesis in, in rat, 740
 Small-molecule insulin receptor sensitizers, 824
 Smoking, cigarette, and microalbuminuria onset in type 1 diabetes, 2842
 Smooth muscle
 accumulation in atherosclerotic lesions, with diabetes, 851
 vascular smooth muscle cells
 apoptosis of, glucose metabolism association, 1171
 proliferation of, stimulation by hypoxia, 1482
 SOD. *see* Superoxide dismutase
 Sodium (Na)-Pi cotransporter, expression during AR42J cell differentiation, S39
 Splanchnic uptake, of glucose
 free fatty acid effects on, in men, 727
 GLP-1 effects on, in type 1 diabetes, 565
 in type 2 diabetes, 1351
Splotch mice, diabetic embryopathy in, 1193
 SREBP-1. *see* Sterol regulatory element-binding protein-1
 Steatosis, hepatic, G6Pase inhibition and, 2591
 Stem cells
 embryonic, insulin production by, 1691
 nestin-positive, differentiation of, 521
 Sterol regulatory element-binding protein-1, intranuclear localization, impairment by indinavir, 1378
 Sterol regulatory element-binding protein-1c, and glucose homeostasis, in diabetic mice, 2425
 Streptozotocin-induced diabetes
 combination benzylamine and vanadate treatment of, in rats, 2061
 plasma 8-hydroxyguanine levels in, in rats, 2837
 reduction by metallothionein, 2040
 reversal with stable allogeneic islet function, in type 1 model, 1227
 Stress, oxidative
 AngII-mediated, inhibition by IGF-1 overexpression, 1414
 endothelial dysfunction induction by, in obesity, 159
 Stretch-induced retinal VEGF-R2 expression, 444

- Stromal cell-derived factor-1, gene variant, and type 1 diabetes, 1211
- Sucrose
cardiomyocyte dysfunction with insulin resistance in rats fed, 1186
neuropeptide Y overexpression and obesity after high-sucrose feeding, 1206
- Sudomotor responses, in sympathetic dysfunction in type 1 diabetes, 436
- Sulfonylurea
nicorandil interactions, 2253
and pulsatile insulin secretion, in type 2 diabetes, 1778
- Sulfonylurea receptor, mutations, insulin dysregulation in congenital hyperinsulinism due to, 322
- Sulfonylurea receptor 1, SUR1 sequence variants, glucose metabolism and, 697
- Superoxide, mitochondrial overproduction by hyperglycemia, 1491
- Superoxide dismutase, $\text{Cu}^{2+}/\text{Zn}^{2+}$, protection against early diabetic glomerular injury in transgenic mice by, 2114
- Suppressor of cytokine signaling-1, and IFN- γ signaling in β -cells, 2744
- Suprachiasmatic nucleus, in daily glucose tolerance rhythms, 1237
- Surgery, cardiac, nitric oxide metabolism during, diabetes and, 2603
- Swine studies
diabetes-induced accelerated atherosclerosis, 1654
dipeptidyl peptidase IV inhibition and glucose-dependent insulinotropic peptide, 1588
insulin effects on liver protein synthesis rates, 947
- Sympathetic injury, sudomotor responses in, 436
- Sympathetic neural activity, adrenal, effects of hypoglycemia on, in rats, 1119
- Systemic insulin delivery, effects on insulin action and VLDL metabolism, 1402
- T**
- T-cells
autoantigens for workshops, 1749
autoreactive, detection in type 1 diabetes, 1749
cytotoxic. *see* Cytotoxic T-lymphocytes
diabetogenic, in β -cell-deficient mice, 763
epitopes, phogrin, in NOD mice, 1729
expansion in type 1 diabetes, 1992
natural killer T-cell deficiency, in NOD mice, 2691
NOD Mouse T-cell Workshop report, 2459
- Tetracycline-inducible (Tet-On) gene expression, in MIN6 cells, S133
- Thiazolidinediones
insulin-sensitizing mechanism of, 1083
and lipid metabolism, 1158
PPAR γ -independent action in rat skeletal muscle, 2309
prevention of FFA-induced insulin resistance by, in male Wistar rats, 2316
- Thymic organ cultures, BB rat adult, 972, 2414
- Thymic tolerance, acquired, indirect allorecognition in, 1546
- Tissue inhibitor of metalloproteinase-1, prevention of cytotoxic islet damage by, 1047
- 3T3-L1 adipocytes
metabolism of, nelfinavir effects on, 1425
VEGF mRNA levels, troglitazone treatment effects on, 1166
- TLK16998, insulin receptor sensitization by, 824
- Toxicity
cytotoxicity
of free fatty acids, in islet cells, 1771
islet, prevention by TIMP-1, 1047
glucotoxicity, β -cell, in *P. obesus* type 2 diabetes, S113
lipotoxicity
 β -cell, 315
in obesity, S118
glucose, 2105
- Training, exercise, and insulin action, in rat, 2659
- Trait differences, PPAR- γ_2 Pro12Ala variant and, 886
- Tramadol, plasma glucose-lowering effects in diabetic rats, 2815
- Transcription factors
 β -cell, mutations, S94
expression in AR42J cell differentiation, S10
- Transplantation
autoislet
long-term, 47
prevention of diabetes by, after pancreatotomy for chronic pancreatitis, 47
fetal endocrine pancreas, differentiation after, in pig-to-mouse model, 962
- islet
autoantibody response to, in type 1 diabetes, 2464
endocrine cell proliferation and differentiation in, 301
HGF effects on, in mice, 2752
outcomes and insulin secretion after, 710
oxygen tension in, rat, 489
kidney-pancreas, effects on atherosclerotic risk factors, 496
pancreas, insulin delivery in, systemic versus portal effects on insulin action and VLDL metabolism, 1402
- Triacylglycerol, islet cell content, increased, hyperglycemia and, in Zucker diabetic fatty rats, 2481
- Tribute, to Bruce R. Zimmerman, 2883
- Triglycerides
cellular accumulation of, free fatty acid cytotoxicity and, 1771
muscle content, in lipoprotein lipase-transgenic mice, 2585
- Troglitazone
effects on plasma VEGF, 1166
GLUT4 translocation by, 1093
in rat adipocytes, 2296
- Troponin I, phosphorylation of, angiotensin II and, 1918
- Tumor necrosis factor- α , effects on insulin action, in human muscle, 1102
- Tungstate, effects in Zucker diabetic fatty rats, 131
- Type 1 diabetes
with albuminuria, antihypertensive therapy effects on renal structure in, 843
animal models, international workshop on lessons from, 2451
anti-CD38 autoantibodies in Caucasians with, 752
atherosclerotic risk factors and endothelial function in, kidney-pancreas transplantation effects on, 496
autoaggressive lymphocytes in, protection from, in transgenic mice, 2700
autoreactive T-cells in, detection of, 1749
 β -cell apoptosis in, S64
discovery of, 217
- early onset or, *SOX1* gene variant and, 1211
exercise-induced glucose uptake in, resistance to, in insulin-resistant skeletal muscle, 1371
 ^{18}F -FDG uptake at hypoglycemia in, in men, 2329
GAD65 autoantibodies from, human recombinant, 1976
gene and cell-replacement therapy for, 2181
GLP-1 effects in, 565
HbA $_{1c}$ levels in, genetic determination of, 2858
hepatic glycogen metabolism in, 392
HLA-DPB1 and, 1200
IA-2 autoantigen, autoimmunity against, by IA-2 gene splicing in pancreas and lymphoid organs, 895
Idd10 and Idd18 loci for, mapping by genetic interaction, in NOD mice, 2633
insulin-resistant skeletal muscle in, resistance to exercise-induced glucose uptake in, 1371
islet allotransplantation in, 277
islet transplantation in, autoantibody response to, 2464
lipid transfer protein activities in, 652
menopause in women with, 1857
microalbuminuria onset in, 2842
nephropathy in, candidate gene screening with, 1214
oral wound healing in, in NOD mice, 2100
pancreatic biopsy in, 1269
polyreactive, Fas function in, 483
QTc dispersion and diurnal BP variations in, 837
renal glucose handling in hypoglycemia in, 2087
serum, effects on cerebellar granule cells, S77
siblings of children with, autoantibody seroconversions in, 2625
streptozotocin-induced, reversal with stable allogeneic islet function, 1227
sympathetic dysfunction in, sudomotor responses in, 436
T-cell expansion in, 1992
by 2-h OGTT criteria, 470
West African patients, CTLA4 point mutation in, 2169
- Type 2 diabetes
ACVR2B mutations associated with, in French patients, 1219
AMPK activation in, 921
Annerin 1 gene in, 2402
anti-CD38 autoantibodies in Caucasians with, 752
Av3hGKRP treatment of, 1813
 β -cell development in, in GK rat model, S84
 β -cell dysfunction in, S160, S169
PDX1 deficiency and, in *P. obesus*, 1799
 β -cell function in, S140
abnormal, evidence for, S172
in GK rat model, S89
 β -cell glucotoxicity in, in *P. obesus* model, S113
 β -cell mass in, S140
expansion of, S189
preservation of, S188
reduction of, S169
 β -cell neogenesis in, S186
 β -cell number in, S169
 β -cell viability in, in GK rat model, S89
chromosome 12q15 locus for, 204
chromosome 18p11 loci for, genome scan for, 675, 1512
in Ashkenazi Jews, 681

- coronary microvascular dilation in, 1180
 diet-induced, rebred Cohen rat model of, 2521
 early onset, insulin secretion in adult offspring of patients with, 1828
 familial aggregation of coronary artery calcium in families with, 861
 gamma globulin levels and, in Pima Indian population, 1598
 gene expression regulation by insulin in, in human skeletal muscle and adipose tissue, 1134
 GK rat model of
 β -cell development in, S84
 β -cell function and viability in, S89
 insulin release in islets in, S108
 GLP-1 and pulsatile insulin secretion in, 776
 gluconeogenesis in, free fatty acid effects on, 810
 glucose-intolerant relatives with, skeletal muscle insulin signaling in, 2770
 glucose-regulated insulin gene expression and PDX-1 deficiency in, in *P. obesus* model, S138
 GLUT4 expression in, 1324
 GSK-3 inhibitors and, 937
 hepatic glucokinase activity in, 1351
 hepatic insulin activity in, 1363
 high-risk subjects, free fatty acid uptake and oxidation in, 2548
 hyperinsulinemia and gluconeogenesis in, 1807
 insulin secretion in, S169
 impaired, PPAR- γ Ala¹² variant and, 891
 pulsatile, sulfonylurea and, 1778
 after intrauterine growth retardation, in rat, 2279
 with ischemic heart disease, endothelial insulin resistance in, 2611
 islet stimulus-secretion coupling in, in *P. obesus* model, 308
 islets in, S1
 KK/Ta mouse model, susceptibility loci, 1943
 late-onset, *IRS-2* gene in, in Finnish and Chinese subjects, 1949
 obese patients with, gene expression profiling of omental fat in, 2822
 obesity-induced, resistance to, in GK gene locus transgenic mice, 622
P. obesus model of
 β -cell glucotoxicity in, S113
 glucose-regulated insulin gene expression and PDX-1 deficiency in, S138
 islet stimulus-secretion coupling in, 308
 p85 α variants and, 690
 parent-of-origin effects in, genome-wide scan for, 2850
 Pax4 gene mutation in, in Japanese, 2864
 PDX1 deficiency and β -cell dysfunction in, in *P. obesus*, 1799
 postprandial GIP and GLP-1 levels in, 609
 PPAR- γ_2 Pro12Ala variant and, 886
 prevention by increased glucokinase, 622
 relatives
 GIP insulinotropic effects in, 2497
 insulin receptor signaling in, 2572
 lactate release per fat cell in, 2344
 risk for
 drinking patterns and, among men, 2390
 IGF-I gene polymorphism and, 637
 skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in, 817
 splanchnic glucose uptake in, 1351
 susceptibility loci contributing to, in KK/Ta mouse model, 1943
 UCP3 content in, 2870
 Tyrosine phosphatase IA-2, preparation for detection of autoreactive T-cells, in type 1 diabetes, 1749
- U**
 Uncoupling protein
 regulatory effects of leptin on, H₁-receptor disruption and, in mice, 385
 upregulation by central histamine infusion, in leptin-resistant obese mice, 377
 Uncoupling protein 2
 free fatty acids and, in insulin secretion, 803
 gene expression, with conjugated linoleic acid, 1149
 overexpression in β -cells, 1302
 Uncoupling protein 3, skeletal muscle content, in type 2 diabetes, 2870
 Uremia, atherosclerotic risk factors and endothelial function in, kidney-pancreas transplantation effects on, 496
- V**
 Vagal cooling, effects on low-dose insulin-induced hypoglycemia response, in dog, 558
 Vanadate, low dosage, combined with benzylamine, in STZ-induced diabetic rats, 2061
 Vascular dysfunction, in diabetic neuropathy, 1927
 Vascular endothelial growth factor
- expression of
 restoration by inhibition of lipid peroxidation, in genetically diabetic mouse, 667
 retinal, induction by cyclic stretch and hypertension, 444
 troglitazone treatment effects on, 1166
 Vascular endothelial growth factor-receptor 2, retinal induction by cyclic stretch and hypertension, 444
 Vascular smooth muscle cells
 apoptosis of, glucose metabolism association, 1171
 proliferation stimulation by hypoxia, 1482
 Vasodilation, coronary, in type 2 diabetes, 1180
 Vasorelaxation, by CO, in diabetes, 166
 Ventromedial hypothalamic nucleus, glucosensing neurons in, 2673
 Very low-density lipoprotein, metabolism of, systemic versus portal insulin delivery effects on, in pancreas transplantation, 1402
 Vitamin C, protective effects against endothelial dysfunction in obesity, 159
- W**
 Weight, birth, diabetes-associated HLA-DQ genes and, 2879
 Weight loss, PPAR- χ_2 gene and, 2172
 Weight loss therapy, with NN2211, 2530
 West African type 1 diabetes patients, *CTLA4* point mutation in, 2169
 Women
 Caucasian, adrenoceptor gene variants and obesity in, 91
 susceptibility to fatty acid-induced peripheral tissue insulin resistance, 1344
 type 1 diabetic, menopause in, 1857
 Wound healing
 oral, in NOD mice, 2100
 stimulation by inhibition of lipid peroxidation, in genetically diabetic mouse, 667
- Z**
 Zimmerman, Bruce R., tribute to, 2883
 Zinc, Cu²⁺/Zn²⁺ superoxide dismutase, protection against early diabetic glomerular injury in transgenic mice by, 2114

Author Index

A

Aalinkeel, R., 2053
 Aarnio, P., 1834
 Abbott, C.R., 2540
 Abella, A., 2061
 Abiru, N., 1274
 Abood, M.E., 992
 Abraham, E.J., 521
 Abraham, L., 2384
 Abu-Amero, S.N., 199
 Accili, D., 1627
 Adams, J.M., 2572
 Adzet, T., 1883
 Afione, S., 515
 Agarwal, A., 515
 Aguilar-Bryan, L., 322
 Ahlberg, S., 2410
 Ahlman, B., 947, 2652
 Ahrén, B., 1030, 1539, 1959, 2225
 Aiello, L.P., 444
 Aizawa, S., 1455
 Aizawa-Abe, M., 227, 1440
 Akanuma, Y., 1455
 Åkerblom, H.K., 2625
 Albers, J.J., 1851
 Alegret, M., 1883
 Alexander, M., 2355
 Alexandre, H., 143
 Ali, A., 1546
 Allen, E.J., 2487
 Allen, J., 2047
 Almgren, P., 2402
 Alt, A., 255
 Altan, V.M., 455
 Altavilla, D., 667
 Amankwah, A.A., 2169
 Amiel, S.A., 1618, 2329
 Amit, M., 1691
 Ämmälä, C., 329
 Amuri, K., 1069
 Anai, M., 573
 Andersen, H.U., 1056
 Andersson, A., 301, 489
 Ando, K., 573
 Andrassy, M., 2792
 André, J., 2809
 Andreelli, F., 1134
 Andreoli, A.M., 1414
 Andrew, C.M., 1618
 Andy, J., 2355
 Angius, E., 1200
 Anno, T., 1166
 Antinozzi, P.A., 1791
 Antonelli, A., 985
 Antony, I., 1180
 Anversa, P., 1414, 2363
 Anyamale, V., 2355
 Aoki, M., 1472
 Apelqvist, Å., 1799
 Appel, M.C., 972
 Appelskog, I.B., 797
 Arch, J.R.S., 105

Argiolas, A., 1950
 Ariel, I., 2763
 Arildsen, H., 837
 Arita, Y., 1126
 Armitage, N., 2633
 Armstrong, J.L., 720
 Arner, P., 1604, 2225, 2410
 Artero, M., 2619
 Asakawa, A., 1206
 Asano, T., 573
 Ashcroft, F.M., 2253
 Assady, S., 1691
 Assimacopoulos-Jeannet, F., 803
 Atkinson, M., 515, 2451
 Atkinson, M.A., 1749
 Atlan-Gepner, C., 462
 Attali, J.-R., 1180
 Auclair, M., 1378
 Augustine, D., 2729
 Austin, M., 2396
 Austin, T.M., 1330
 Avrithi, D., 91
 Awata, T., 891
 Aynsley-Green, A., 329, 2763
 Azzout-Marniche, D., 2425

B

Bach, F.H., 1983
 Bachmann, O.P., 2579
 Baier, L., 901
 Bailbé, D., 1562
 Bain, S.C., 184, 1200
 Baj, G., 752, 985
 Baker, L., 322
 Bakhos, N., 2673
 Bandsma, R.H.J., 2591
 Banfi, C., 1522
 Bao, M., 2691
 Barbano, D.M., 1149
 Barber, R., 184
 Barberà, A., 131
 Bardelli, M., 2619
 Barnes, P.D., 329
 Barnett, A.H., 1200
 Barrett, E., 2682
 Barzilay, N., 348, 2786
 Barzilay, J.L., 2384
 Bashan, N., 1425
 Basu, A., 565, 1351
 Basu, R., 565, 1351
 Batlle, D., 1482
 Batterham, R.L., 2540
 Battezzati, A., 277
 Bauman, D.E., 1149
 Båvenholm, P.N., 1449
 Beasley, J., 733
 Beavers, L.S., 2822
 Bécard, D., 2425
 Becker, R., 876
 Beck-Nielsen, H., 1324, 1363
 Beguinot, F., 1244
 Beisswenger, P.J., 2139
 Bektas, A., 204
 Bell, G., 199
 Bell, G.I., 694, 2013
 Belsanti, G., 2709
 Benedini, S., 277
 Bennett, P.H., 1598, 2850
 Bennett, S.T., 199
 Bentley, B., 123
 Berg, C., 947
 Bergeron, R., 1076
 Berggren, P.-O., 797
 Berglund, L., 690
 Bergman, R.N., 399, 886
 Bergonzelli, G.E., 2666
 Bergsten, P., 51, 1785, 2737
 Berkovich, I., 2260
 Berman, D.M., 2172
 Berne, C., 690
 Bernex, F., 2021
 Berney, T., 270, 1983
 Bernroider, E., 392
 Berria, R., 2572
 Bertry-Coussot, L., 2425
 Bertuzzi, F., 1290, 2464
 Bianchi, G., 1844
 Bidasee, K.R., 455
 Biden, T.J., 2210, 2237
 Bierhaus, A., 2792
 Bigam, D., 710
 Bingham, C., 2047
 Binert, C., 727
 Bischof, L.J., 502
 Bischof, M.G., 392
 Björck, R.J., 1495
 Björholm, M., 2770
 Blaak, E.E., 2548, 2870
 Blair, L.A., 283
 Bleich, D., 1047
 Bloom, S.R., 248, 2540
 Bock, T., 1553, 1763
 Boden, G., 810, 1612
 Bodkin, N.L., 1126
 Boehnke, M., 886
 Boeri, D., 1432
 Boettcher, B.R., 1813, 2287
 Bogardus, C., 901, 1828
 Bohlooly-Y, M., 1539
 Boirie, Y., 2652
 Boitard, C., 1211
 Bolinder, J., 1604
 Bona, G., 483
 Bonavaud, S.M., 720
 Bondjers, G., 2126
 Bonifacio, E., 2451, 2464
 Bonini, P., 1290
 Bonissoni, S., 483
 Bonner-Weir, S., 2231
 Bonny, C., 77
 Borghouts, L.B., 2870
 Bornfeldt, K.E., 851
 Bortoletto, M., 2619
 Bosco, D., 1039
 Bosi, E., 2464

Bottarel, F., 483
 Bouchard, C., 614, 697
 Boulard, O., 2874
 Bouloumié, A., 2080
 Boulton, M., 2641
 Bowden, D.W., 861
 Boyd, A.E., III, 56
 Bozzali, M., 1950
 Braakhuis, A., 771
 Braghi, S., 2464
 Braiman, L., 255
 Brandhorst, D., 277
 Brandhorst, H., 277
 Braun, A., 886
 Brechtel, K., 2579
 Breda, E., 150
 Brendel, M.D., 277
 Bretzel, R.G., 277
 Briaud, I., 315
 Bringer, J., 2164
 Brizi, M., 1844
 Broadley, S., 184
 Broca, C., 1311
 Brown, D., 895
 Browne, P.O., 686
 Brownlee, M., 1491
 Broy, L.F., 436
 Brozinick, J.T., Jr., 593
 Brunmaier, B., 2309
 Brusco, A., 483
 Bryner, K.D., 436
 Buchanan, T.A., 886
 Buckingham, R.E., 1021
 Bugianesi, E., 1844
 Buhl, E.S., 12
 Buijs, R.M., 1237
 Bullmore, E., 1618
 Bulmer, K., 2729
 Burant, C.F., 2013
 Burcelin, R., 1282, 1720
 Burger, H.-J., 2591
 Burke, J.P., 1857
 Burkey, B.F., 1863
 Burkly, L.C., 270
 Busch, A.K., 584
 Buschard, K., 1763
 Buse, M.G., 2419
 Buteau, J., 2237
 Butler, P.C., 2001
 Buzzetti, R., 184

C

Cabrero, A., 1883
 Cadario, F., 483
 Cai, T., 2406
 Cai, X.J., 105
 Caillat-Zucman, S., 1211
 Cairns, F., 2148
 Camargo, C.A., Jr., 2390
 Cambien, F., 1214
 Camejo, G., 2126
 Camilleri, M., 565
 Campo, G.M., 667

- Candido, R., 2619
 Candigliota, M., 159
 Capeau, J., 1378
 Caplan, S.L., 1813, 2287
 Capulong, E., 810
 Caradonna, Z., 1290
 Carandente, O., 1290
 Cardin, S., 558, 1872, 2487
 Cardozo, A.K., 909, 2219
 Carlson, E.C., 2040
 Carlsson, M., 675
 Carlsson, P.-O., 489
 Caro, J.F., 2822
 Caron, M., 1378
 Carpené, C., 2061
 Carpenter, L., 2210, 2237
 Carpentier, A., 1402
 Carr, J.J., 861
 Carraro, M., 2619
 Carretta, R., 2619
 Carruba, M.O., 601
 Caruso, M., 1244
 Cases, J.A., 348
 Cassader, M., 752
 Castellani, L.W., 643
 Cattani, P., 270, 1983
 Cattin, M.R., 2619
 Cattra, M.S., 1402
 Cavadas, C., 2666
 Cavaghan, M., 1828
 Cavaghan, M.K., 150
 Cavallari, V., 667
 Cavallo-Perin, P., 752
 Cayeux, C., 727
 Cazzolli, R., 2210
 Cebrian, A., 2752
 Cerasi, E., 308, 1799
 Ceravolo, R., 159
 Cersosimo, E., 2087
 Cerutti, F., 483
 Cesselli, D., 2363
 Cha, S., 2100
 Chagnon, M., 614
 Chagnon, Y.C., 614, 697
 Chan, C.B., 1302
 Chan, G., 675
 Chan, S.L.F., 340
 Chandramouli, V., 1872
 Chang, C.J., 2815
 Chang, J.-C., 2598
 Chang, T.-J., 2598
 Chapman, H.D., 1992
 Chapman, J.C., 329
 Chardès, T., 1311
 Charlton, M., 947, 2652
 Charron, M.J., 1149
 Chatenoud, L., 2459
 Chatham, J.C., 1171
 Chatterjee, V.K.K., 686
 Chayen, S., 681
 Chen, H., 2040
 Chen, H.-Q., 1580
 Chen, J., 2792
 Chen, W., 1863
 Chen, X., 810
 Cheng, J.-T., 1206, 2815
 Chernausk, S.D., 1110
 Cherrington, A.D., 367, 558, 622, 1872, 2487
 Chesnut, K., 515
 Cheung, S., 1918
 Chi, T.-C., 2815
 Chiba, S., 376, 385
 Chiba, Y., 573
 Childhood Diabetes in Finland Study Group, the, 2625
 Chimenti, S., 1414
 Chiu, P.P.L., 763
 Choi, C.S., 418
 Choi, J.Y., 2837
 Chong, M.M.W., 2744
 Christiansen, E., 2611
 Christiansen, J.S., 96, 2301
 Chua, S.C., Jr., 425
 Chuang, L.-M., 2598
 Chung, M.H., 2837
 Cirillo, G., 2157
 Cisternino, C., 1950
 Civelek, V.N., 56
 Clark, M.G., 2659
 Claussen, C.D., 2579
 Clemmons, D.R., 32
 Clermont, A., 444
 Cline, G.W., 1076, 1263
 Cnop, M., 1771, 2514
 Cobelli, C., 150
 Coffey, C.S., 558
 Coggins, M., 2682
 Coghlan, M., 937
 Cohen, M.A., 2540
 Colhoun, H.M., 652
 Collins, F.S., 886
 Collins, M.D., 1193
 Colonna, M., 667
 Combatisaris, T., 1149
 Compston, A., 184
 Condorelli, G., 1244
 Conigrave, K.M., 2390
 Connell, J.M.C., 2148
 Connelly, S., 1813, 2287
 Conner, L.J., 2822
 Considine, R.V., 2199
 Contreras, J.L., 1227
 Cook, J.A., 1330
 Coon, B., 2700
 Cooney, G.J., 411
 Cooper, G.J.S., 1821
 Coppey, L.J., 1927
 Coraddu, F., 184
 Corbett, J.A., 283
 Cordell, H., 1200
 Cordell, H.J., 184
 Cordi, S., 143
 Corkey, B.E., 56
 Corominola, H., 2822
 Corrias, A., 483
 Cosgrove, K.E., 329
 Costanzo, B.V., 831
 Courtoy, P.J., 143
 Cox, N.J., 694, 2013
 Cranston, I., 2329
 Cras-Méneur, C., 1219, 1571
 Craven, P.A., 2114
 Cristallo, M., 496
 Cristobal, C.P., 824
 Cristofalo, V., 2641
 Crook, E.D., 2355
 Cros, G., 2164
 Croset, M., 740
 Crow, M.T., 1495
 Cruz, W.S., 353
 Cryer, P.E., 1911
 Cucca, F., 184, 1200
 Cucinotta, D., 667
 Cui, L., 1149
 Cummings, D.E., 1714, 2555
 Currie, K.P.M., 2013
 Cushman, M., 2384
 Cushman, S.W., 593
 Cusi, K., 2572
 Cusin, I., 601
 Cuthbertson, D., 470
 Cuthbertson, D.D., 1735
 Czernichow, P., 1571, 2021
D
 Da Costa, A., 1720
 Dahl, D.B., 2579
 Dahlmans, V.E.H., 2585, 2779
 Damaris Molano, R., 1706
 Damberg, G.S., 2203
 Damotte, D., 2874
 Damsgaard, E.M., 630
 D'Angelo, A., 496
 Daniel, P.B., 521
 Danielsen, P., 1588
 Danoy, P.A., 184
 Danska, J.S., 763
 Darville, M., 2219
 Darville, M.I., 1741
 Daurès, J.P., 2164
 Davalli, A.M., 1290, 2709
 Davidoff, A.J., 1186
 Davidson, E.P., 1927
 Davidson, M.B., 1186, 1222
 Davis, H.R., 1330
 Deacon, C.F., 609, 1588, 2497
 Deeney, J.T., 56
 Defoort, C., 462
 DeFranco, S., 483
 DeFronzo, R.A., 2572
 DeHaven, J.E., 2419
 De Hertogh, R., 143
 Dela, F., 1834
 del Bosque-Plata, L., 694
 Delenne, B., 462
 De Leo, D., 1302
 del Giudice, E.M., 2157
 Del Maschio, A., 496
 Del Parigi, A., 901
 De Matos, F., 1219
 Dence, C.S., 1911
 Denner, L., 1495
 Dennis, K.E., 2172
 Deodato, B., 667
 Depaz, H.A., 1546
 D'Ercole, A.J., 32
 DeRubertis, F.R., 2114
 Desai, U.J., 1813, 2287
 de Souza, C.J., 1863
 Després, J.-P., 614
 Devanarayan, V., 707
 De Virgiliis, S., 1200
 Dhalla, N.S., 2133
 Dhillon, W.S., 2540
 Diabetes Prevention Trial of Type 1 Diabetes Study Group, 470
 Dianzani, U., 483
 Di Carlo, V., 277, 496
 Dietz, S., 1311
 Diez, J., 895
 Dillon, J.S., 56
 DiLorenzo, T.P., 1992
 Dinçer, Ü.D., 455
 Dionne, I.J., 91
 Di Paola, R., 831, 1950
 Di Toro, R., 2157
 Dixon, K., 622
 Dobashi, R., 1206
 Dobbins, R.L., 123
 Docherty, K., 2244
 Dominguez, J., 131
 Dominiczak, A.F., 2148
 Donath, M.Y., 69, 1683, 2105
 Donelan, M.J., 2029
 Dong, M., 1863
 Donnay, I., 143
 Donovan, C.M., 399
 Doria, A., 204
 Dorman, J.S., 1857
 Douglas, J.A., 886
 Doyle, P.J., 411
 DPT-1 Participating Investigators, the, 1735
 Drucker, D., 1720
 Du, X.-L., 1491
 Dubois-Laforgue, D., 1211
 Ducluzeau, P.-H., 1134
 Ducret, R., 1336
 Dudbridge, F., 1200
 Dumas, F., 1666
 Dunlap, J.A., 1927
 Dunne, M.J., 329
 Dupont, S., 1219
 DuPrat, L., 681
 D'Urso, L., 2157
 Dutta, K., 1186
 Duvivier-Kali, V.F., 1698
 Dyntar, D., 69, 2105
E
 Eaves, I.A., 184
 Ebbelhøj, E., 837
 Ebihara, K., 227, 1440
 Eckel, R.H., 1064
 Eckhard, M., 277
 Eckhardt, M., 1863
 Eckhoff, D.E., 1227
 Edelstein, D., 1491
 Edgerton, D.S., 558, 1872
 Edlund, H., 1799
 Edwards, K., 2396
 Efanov, A.M., 797
 Efendic, S., 308, 797, 1449
 Efrat, S., 980, 2260
 Egnell, A.-C., 2126
 Ehnholm, C., 886
 Eisenbarth, G., 2451
 Eisenbarth, G.S., 895, 1274, 1735
 Eizirik, D.L., 909, 1741, 1771, 2219
 Ekberg, I., 921
 Eldar-Finkelman, H., 1171
 Elghazi, L., 1571, 2021
 Elimban, V., 2133
 Ellard, S., 2047
 Elliott, J.F., 710
 Ellis, T., 515
 El Mkaem, S.A., 2164
 Eloy, L., 2874
 Elrick, L.J., 2244
 Embury, J., 1706
 Emoto, M., 1166
 Emshwiller, M., 367, 1872
 Endl, J., 1749
 Engerman, R.L., 1636

- Eppenberger, H.M., 2105
 Eppenberger-Eberhardt, M., 2105
 Epstein, P.N., 2040
 Ercolino, T., 1950
 Erdos, M.R., 886
 Eriksson, J.W., 2344
 Eriksson, P., 1522
 Erkinjuntti, M., 1371
 Esser, V., 123
 European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT) Study Group, 843
 Evans, J.L., 404
 Evans, M., 1618
 Evans, M.L., 105
- F**
- Fabris, B., 2619
 Fabris, R., 601
 Faccini, L., 2619
 Fakhrai-Rad, H., 2737
 Fallahi, P., 985
 Fanelli, B., 1813, 2287
 Fanelli, C.G., 1911
 Fantus, I.G., 83, 2376
 Farley, C., 1330
 Fasy, E., 2682
 Federici, M., 1290
 Federspil, G., 601
 Feener, E.P., 444
 Fekkes, M.L., 1237
 Feng, Z., 2786
 Fenjves, E.S., 515
 Ferber, S., 1799
 Fermo, I., 496
 Fernandez, A.M., 1110
 Fernández-Alvarez, J., 131
 Ferrannini, E., 985, 1807
 Ferrante, A.W., Jr., 2268
 Ferré, P., 2425
 Ferreira, L. D.M.C.-B., 1064
 Ferretti, J., 2087
 Ferry, R.J., Jr., 322
 Fey, S.J., 1056
 Filipsson, K., 1959
 Finegood, D.T., 1021
 Fink, B.D., 1119
 Finnerty, J., 534
 Fior, F., 2619
 Fiordaliso, F., 1414, 2363
 Fiorina, P., 496
 Fiorotto, A., 2619
 Fisher, J., 1397
 Flattem, N., 367
 Fledelius, C., 2530
 Fleischer, N., 348
 Flotte, T., 515
 Fluteau, G., 2874
 Foisy, S., 2237
 Foley, T.P., 1857
 Folli, F., 1290
 Fontana, A., 1683
 Ford, G.C., 747
 Forest, C., 1378
 Forlani, G., 1844
 Formisano, P., 1244
 Forsblom, C., 675
 Foulle, F., 2425
 Fox, A.P., 2013
 Fraker, C., 1706, 1983
- Francis, M.K., 2641
 Frascerra, S., 1807
 Fray, R.S., 1714
 Freedman, B.I., 861
 Freund, N., 1069
 Frias, J.P., 1344
 Friel, E., 291
 Friemann, S., 277
 Fritsche, A., 882, 1143, 2161
 Frittitta, L., 831, 1950
 Fritz, G., 1643
 Fröberg, S., 921
 Froguel, P., 1219
 Frøland, A., 630
 Fruchart, J.-C., 2809
 Frystyk, J., 1110
 Fu, A., 947
 Fujii, N., 241, 921
 Fujimiya, M., 1206
 Fujimoto, Y., 622
 Fujishiro, M., 573
 Fujita, T., 573
 Fujitani, Y., 2864
 Fukushima, Y., 573
 Fuller, J.H., 652
 Funabiki, K., 1943
 Funahashi, T., 1126, 2094
 Funaro, A., 752
 Fürsinn, C., 2309
 Furuta, H., 2864
 Furuta, M., 534
 Furutani, Y., 113
 Futers, T.S., 1505, 2646
- G**
- Gabriely, I., 348
 Galski, R.A., 2822
 Gagen, K., 1863
 Gaillard, R.C., 2666
 Gale, E.A.M., 217
 Galeano, M., 667
 Galiñanes, M., 2603
 Galitzky, J., 2080
 Galli, J., 2737
 Galuska, D., 1149
 Garchon, H.-J., 2874
 García-Ocaña, A., 2752
 Garlick, P., 2087
 Garroville, M., 1546
 Gartsbein, M., 255, 1627
 Garza, D., 895
 Gastaldelli, A., 1807
 Gaster, M., 1324
 Gautier, J.-F., 1828
 Gavrilova, O., 1440
 Gellett, J.S., 1927
 Geoghegan, K.F., 2029
 Gerhardinger, C., 175
 Gerich, J.E., 905
 Gerin, L., 1531
 Gerlach, M.J., 521
 German, M.S., 63, 694, 928
 Gerrity, R.G., 851, 1654
 Gertz, S.J., 2279
 Ghatei, M.A., 248, 2540
 Ghatescu, L.D., 1666
 Giacca, A., 1402
 Giampietro, V., 1618
 Giandomenico, G., 1522
 Gibbons, G.H., 1171
 Gibbs, E.M., 593
 Gilchrist, F., 1200
- Giorgino, F., 2709
 Giorgino, R., 2709
 Giunti, S., 752
 Gjessing, H.J., 630
 Glaser, B., 322, 329, 681, 2763
 Glatzer, O., 1643
 Glauser, M., 2666
 Gleason, C.E., 2481
 Glimcher, L.H., 39
 Glorian, M., 1378
 Goforth, P.B., 992, 2192
 Goldberg, H.J., 2376
 Goldfine, A.L., 404
 Goldfine, I.D., 404, 824, 2323
 Goldman, J.K., 502
 Goldstein, B.J., 83
 Gomis, R., 131
 Gonelle-Gispert, C., 1039
 Gonzalez, C., 2874
 Gonzalez, F.J., 2809
 Goodyear, L.J., 241, 921
 Gopinathan, R., 1546
 Goran, M.I., 2444
 Goto, A.M., 643
 Goto, T., 2337
 Gotoda, T., 891
 Gould, G.W., 2148
 Gourdon, L., 1515
 Gower, B.A., 2444
 Graci, S., 1950
 Graham, T., 2349
 Graier, W., 1643
 Grant, P.J., 1505, 2646
 Granzotto, M., 601
 Gras, F., 2309
 Graser, R.T., 1992
 Gray, D., 91
 Greenbaum, C.J., 470
 Greenberg, A.S., 1425
 Greene, K., 2355
 Greenhaff, P.L., 18
 Greer, F., 2349
 Greiner, D.L., 972
 Gribble, F.M., 2253
 Griffen, S.C., 63
 Grigorescu, F., 2164
 Grimberg, A., 322
 Grimsby, J., 622
 Grippo, J.F., 622
 Gris, J.C., 2164
 Groop, L.C., 675, 2402
 Gross, D.J., 1799
 Gross, R., 1311
 Grouzmann, E., 2666
 Gruetter, R., 2203
 Guerre-Millo, M., 2809
 Gugliucci, A., 1666
 Guinovart, J.J., 131
 Güner, S., 455
 Gunther, V.J., 2287
- H**
- Ha, X.F., 1302
 Haap, M., 2579
 Habener, J. F., 521, 1553
 Hagström-Toft, E., 1604
 Haidacher, J., 1495
 Hainault, I., 2425
 Häkkinen, A.-M., 2337
 Halavaara, J., 2337
 Halban, P.A., 1039, 2181
 Halestrap, A.P., 361
- Hall, J.L., 1171
 Halsall, D.J., 686
 Halse, R., 720, 1102
 Hamaguchi, K., 1012
 Hamilton, J.A., 56
 Hammes, H.-P., 2641
 Hamsten, A., 1522
 Han, B., 2837
 Han, X., 1047
 Hanabusa, T., 2864
 Hanafusa, T., 891, 1269
 Handberg, A., 1324
 Hani, E.H., 1219
 Hanis, C.L., 2013
 Hanna, L.S., 2842
 Hanna, S.T., 166
 Hannaert, J.C., 1771
 Hänninen, A., 771
 Hansen, Å.P., 1778
 Hansen, B.C., 1126
 Hansen, B.F., 584
 Hansen, K.W., 837
 Hansen, L., 690
 Hansen, L.L., 584
 Hansen, P.A., 2013
 Hansen, T., 690
 Hanson, R.L., 1598, 2850
 Hara, K., 891
 Harada, S., 2169
 Harbis, A., 462
 Harding, A.-H., 686
 Hardy, M.A., 1546
 Hargrove, D.M., 593
 Häring, H., 876, 882, 1143, 2161, 2579, 2792
 Harman-Boehm, I., 1425
 Harmon, J.S., 315, 2481
 Harper, I., 901
 Harrison, L.C., 771, 2459
 Haruta, T., 1083, 1891
 Haskins, K., 2459
 Hastings, J.R., 2487
 Hata, Y., 444
 Hattersley, A.T., 2047
 Havekes, L.M., 2585, 2779
 Haversler Foss, C., 630
 Hayashi, M., 1012, 1464
 Hayashi, T., 227, 1093, 1440, 2296
 Haynes, W.G., 1119
 He, J., 817
 Heath, W.R., 771
 Heckbert, S.R., 2384
 Heilmann, C., 1056
 Heiman, M.L., 707
 Heimberg, H., 1, 2219
 Heitmeier, M.R., 283
 Heller, R.S., 1553
 Hemmings, B.A., 690
 Henchoz, E., 727
 Hendel, H., 1211
 Henle, T., 2792
 Henquin, J.-C., 540
 Heremans, Y., 2219
 Herlein, J.A., 1119
 Herling, A.W., 2591
 Hernandez, R., 2563
 Herold, K., 980
 Hessel, P., 18
 Hesselink, M.K.C., 2870
 Heutink, P., 637
 Hevener, A.L., 399, 2316

- Higaki, Y., 241
 Higo, K., 139
 Hiriart, M., 1755
 Hirose, S., 1943
 Hirshman, M.F., 241, 921
 Ho, I.-C., 39
 Hobbs, G.R., 436
 Hoeldtke, R.D., 436
 Hoffstedt, J., 2410
 Hofman, A., 637
 Hofmann, M., 2792
 Ho-Kim, M.-A., 614
 Holloszy, J.O., 1397
 Holm, C., 2225
 Holman, G.D., 12
 Holmdahl, R., 184
 Holness, M.J., 2729
 Holst, J.J., 565, 609, 776, 1030, 1363, 1588, 2497
 Homko, C., 1612
 Honda, Y., 867
 Hong, M., 2792
 Hoorens, A., 551, 1771
 Hopkins, D., 1618
 Horikawa, Y., 694, 2013
 Horn, T., 1553
 Hornbuckle, L.A., 502
 Horvath, G.G., 436
 Horwitz, M., 980
 Hosoda, K., 227, 1093, 1440, 2296
 Hother-Nielsen, O., 1363
 Hotta, K., 1126, 2094
 Hou, L., 2169
 Houseknecht, K.L., 1149
 Hovland, D.N., Jr., 1193
 Howell, S., 2139
 Hribal, M., 1290
 Hsu, W.H., 2598
 Hu, B.F., 2390
 Hua, H., 2376
 Hubbard, W.J., 1227
 Hücking, K., 2497
 Hudson, B.I., 1505, 2646
 Hudson, R., 2349
 Hughes, A., 2700
 Hughes, J.N., 204
 Hui, H., 785
 Hull, R.L., 2514
 Humpert, P.M., 2792
 Humphreys-Beher, M.G., 2100
 Hurot, J.-M., 740
 Hussain, K., 2763
 Hutton, J., 895
 Hutton, J.C., 502, 1729
 Huypens, P., 1
 Hyrkkö, A., 675
- I**
 Iacopino, S., 159
 Igawa, K., 367
 Iglesias, M.A., 411
 Ihlemann, N., 2611
 Ikeda, Y., 584
 Ikegami, H., 891
 Iliadou, A., 2410
 Imagawa, A., 1269
 Imes, S., 710
 Inoue, G., 227, 1093, 1440, 2296
 Inoue, I., 891
 Inoue, R., 1093
 Inui, A., 1206
- Inukai, K., 573
 Inverardi, L., 270, 515, 1706, 1983
 Ionesco-Tirgoviste, C., 184
 Isaksson, O.G.P., 1539
 Ishibashi, O., 1083
 Ishii, S., 2438
 Itoh, N., 1269
 Itskovitz-Eldor, J., 1691
 Iwahashi, H., 1269
 Iwamoto, Y., 694, 891
 Iwasaki, N., 694, 891
 Iwata, M., 1083, 1891
- J**
 Jacinto, S.M., 1158
 Jackson, P.A., 558
 Jackson, R., 1735
 Jacob, C.O., 184
 Jacob, H.J., 2521
 Jacob, S., 876, 2579
 Jacques, H., 1901
 Jahn, L., 2682
 James, A.J., 2047
 James, D.J., 2148
 Janez, A., 2316
 Jannsen, J.A., 637
 Jansson, J.-O., 1539
 Jansson, P.-A.E., 2344
 Jauniaux, E., 199
 Jayaraman, S., 1706
 Jenkins, S., 1227
 Jenkinson, C., 901, 2572
 Jensen, C.B., 2770
 Jensen, D.R., 1064
 Jensen, J., 1553
 Jensen, M., 1351
 Jéquier, E., 727
 Jessen, N., 12
 Jetton, T.L., 622
 Jin, M.-X., 1546
 Jirholt, J., 184
 Joannis, D.R., 195
 Jobin, C., 2219
 Johnson, C.M., 1351
 Johnson, D., 2822
 Johnson, E.A., 980, 1992
 Johnston, C.L., 886
 Joner, G., 2879
 Jong, M.C., 2585, 2779
 Jonkers, F.C., 540
 Jørgensen, J.O.L., 96, 2301
 Joseph, J.W., 1302
 Joyce, S., 1992
 Juhasz, O., 1495
 Juhel, C., 462
 Juhl, C., 776
 Juhl, C.B., 1778
 Jury, K., 1976
- K**
 Kaburagi, Y., 1455
 Kadowaki, T., 113, 891, 1455
 Kaga, T., 1206
 Kähler, H., 1056
 Kahn, A., 1515
 Kahn, S.E., 2181, 2514
 Kaiser, N., 69, 308, 1683, 1799
 Kajimoto, Y., 2864
 Kajio, H., 2029
 Kajstura, J., 1414, 2363
 Kaleko, M., 1813, 2287
 Kalsbeek, A., 1237
- Kamegai, J., 2438
 Kaneda, Y., 1472
 Kang, B.P.S., 1918
 Kangawa, K., 227
 Kapturczak, M., 515
 Karhapää, P., 1949
 Kärkkäinen, P., 1949
 Karlsen, A.E., 1056
 Kasper, M., 2792
 Kassem, S.A., 2763
 Kassis, N., 2874
 Kasuga, M., 891, 1206
 Kato, H., 113
 Kato, K., 113
 Kaufman, D.L., 2459
 Kaul, S., 2682
 Kawaguchi, Y., 891
 Kawahara, J., 1083, 1891
 Kawanaka, K., 1397
 Kawata, S., 1269
 Kay, T.W.H., 2451, 2744
 Keizer, H.A., 2870
 Käläläinen, P., 1949
 Kelemen, K., 1729
 Kelley, D.E., 817, 1253, 2069
 Kelly, A., 322
 Kelpe, C.L., 315
 Kendall, D.M., 47
 Kent, A., 2133
 Kenyon, N., 1706
 Kenyon, N.S., 270
 Kergoat, M., 1562
 Kern, T.S., 1636, 1938
 Khan, A., 308
 Khan, F.A., 2192
 Kieffer, T.J., 1004
 Kiens, B., 265
 Kihara, S., 2094
 Kikuchi, M., 573
 Kim, J.H., 2837
 Kim, J.M., 2837
 Kim, M.S., 248, 2837
 Kim, S., 1472
 Kim, S.K., 2837
 Kim, S.Y., 2837
 Kimsey, T., 1654
 Kimura, S., 113, 1455
 Kin, T., 710
 Kinard, T.A., 992
 Kingsnorth, A., 199
 Kirby, B.M., 2001
 Kishida, K., 2094
 Kistorp, C.N., 2611
 Kjems, L.L., 2001
 Klarskov, L., 1588
 Klein, D., 1706
 Klenk, E.S., 2199
 Klip, A., 1464
 Klötting, I., 2792
 Kneteman, N.M., 710
 Knip, M., 2625
 Knowler, W.C., 1598, 1828, 2850
 Knudsen, L.B., 2530
 Knudsen, S.T., 837
 Knuuti, M.J., 1371
 Kobayashi, M., 1083, 1891, 1943
 Kober, L., 2611
 Kobes, S., 2850
 Koch, M., 882
 Koeleman, B.P.C., 1200
 Kohanski, R.A., 824
 Kojima, M., 227
- Kojwang, D., 1021
 Komuro, R., 2094
 Kono, D.H., 184
 Konrad, D., 1464
 Koo-McCoy, S., 322
 Korbitt, G.S., 710
 Korchak, H.M., 56
 Korsgren, O., 962
 Korshennikova, E., 2337
 Kostner, G.M., 1643
 Kowalski, T.J., 425
 Kowluru, A., 1580
 Kowluru, R.A., 1938
 Koyama, S., 867
 Kozłowski, M., 2323
 Kozłowski, M.R., 824
 Kraegen, E.W., 411, 1821
 Kraemer, F.B., 1455
 Krakoff, J., 1598
 Kramer, D.L., 24
 Krarup, T., 609, 2611
 Kratky, D., 2585
 Krebs, M., 392
 Krischer, J.P., 470, 1735
 Krolewski, A.S., 204, 2842
 Krssak, M., 392
 Kruhoffer, M., 909
 Kruszynska, Y.T., 1344
 Kubota, N., 1455
 Kuchinski, N., 329
 Kuipers, F., 2591
 Kuller, L.H., 1857, 2384
 Kulmala, P., 2625
 Kuriyama, H., 2094
 Kuroki, T., 255
 Kuusisto, J., 1949
 Kvist-Reimer, M., 1959
 Kwok, C.K., 1857
 Kwon, G., 353
- L**
 Laakso, M., 1949, 2396
 Läärrä, E., 2625
 Laborde, E., 824
 Lacaille, M., 614
 Laffel, L.M.B., 2842
 La Fleur, S.E., 1237
 Lafontan, M., 2080
 Laguna, J.C., 1883
 Lai, R., 83
 Lairon, D., 462
 Lajoix, A.-D., 1311
 Lakey, J.R.T., 710
 Lamberts, S.W.J., 637
 Lameloise, N., 803
 Lamhamedi-Cherradi, S.-E., 2874
 Lampis, R., 1200
 Landau, B.R., 1872
 Langefeld, C.D., 861
 Lanz, K.J., 47
 La Rocca, E., 496
 Larsen, I., 710
 Larsen, M.R., 1056
 Larsen, P.J., 2530
 Larsen, P.M., 1056
 Larsson, O., 797
 Latgé, C., 462
 Laurent, D., 1263, 1863
 Lauritsen, T., 1834
 Lauro, R., 1290
 Lautier, C., 2164

- Laval, S., 184
 Lavebratt, C., 2410
 Lavigne, C., 1901
 Laville, M., 1134
 Laviola, L., 2709
 Lawrence, J.C., Jr., 404
 Laychock, S.G., 2505
 Le, N., 1397
 Lebed, B., 1612
 LeBoeuf, R.C., 2555
 Leclerc, I., 1515
 Lecoeur, C., 1219
 Ledoux, S., 1180
 Lee, F.N., 418
 Lee, H.K., 2837
 Lee, J.C., 928
 Lee, J.-P., 2013
 Lee, M.R., 2126
 Lee-Chan, E., 2451
 Leeman, R., 909
 Leemans, R., 2219
 Lefebvre, P., 2001, 2164
 Lehmann, R., 1683
 Lehtovirta, M., 675
 Leibel, R.L., 425, 2268
 Leibowitz, G., 1799
 Lelièvre-Pégorier, M., 1069
 Lemieux, S., 614, 1612
 Lenzi, M., 1844
 Lenzner, C., 1515
 Leonard, T., 1021
 Leri, A., 1414, 2363
 Lernmark, Å., 2181
 Le Roith, D., 1110
 Leslie, R.A., 105
 Leslie, R.D.G., 2858
 Le-Tien, H., 83
 Levak-Frank, S., 1643, 2585
 Levin, B.E., 2673
 Levin, K., 1363
 Lévi-Strauss, M., 2874
 Lewis, G.F., 1402
 Lewitzky, S., 675, 681
 Li, B., 1414
 Li, H., 270, 1970
 Li, M., 2323
 Liao, T., 2268
 Lillaz, E., 752
 Limana, F., 1414, 2363
 Lin, J., 681, 694, 928
 Lin, J.-M., 2737
 Lindgren, C., 675
 Lindgren, C.M., 2402
 Lindley, K.J., 329, 2763
 Lindner, J., 2682
 Lindsay, R.S., 1598, 2850
 Liss, P., 489
 Lister, C.A., 105
 Lithell, H., 690
 Liu, I.-M., 2815
 Liu, I.-Min, 1206
 Liu, J.-L., 1110, 1539
 Liu, M.-W., 2598
 Liu, S.-M., 425
 Liu, X.H., 2431
 Ljung, B., 1158
 Ljungqvist, O., 921
 Lo, D., 39
 Lobashevsky, A., 1227
 Lobbens, S., 1219
 Loblein, K., 876
 Lochhead, P.A., 937
 Loddo, M., 1200
 Loffredo, G., 483
 Loiler, S., 515
 Lombardi, A.M., 601
 López-Talavera, J.-C., 2752
 Lord, C.J., 2633
 Lorentzon, M., 2126
 Lorenzi, M., 175, 1432
 Lorenzo, M., 2563
 Loviscach, M., 2579
 Lu, F.-H., 2815
 Luan, J., 686
 Lukinius, A., 962
 Lum, R.T., 824
 Lund, D.D., 1927
 Lund, S., 12
 Lundén, G.Ö., 2126
 Lusus, A.J., 643
 Luther, T., 2792
 Luthman, H., 2737
 Luzzi, L., 277
 Lynn, F.C., 1004
 Lyons, P.A., 2633

M
 Ma, X.H., 348
 Macaraeg, G.B., 1344
 Macari, F., 2164
 Machado, A.F., 1193
 Machann, J., 2579
 Machicao, F., 876, 882, 2161
 Maclaren, N., 1735
 Madaus, A., 882, 2161
 Maddux, B.A., 404, 2323
 Madsbad, S., 609, 2770
 Madsen, O.D., 1553
 Maeda, E., 891
 Maeda, N., 2094
 Maedler, K., 69, 1683, 2105
 Maerker, E., 882
 Maezono, K., 2572
 Maffi, P., 2464
 Maggi, L.B., Jr., 283
 Magnus, P., 2879
 Magnuson, M.A., 622
 Maiello, M., 1432
 Maier, T., 2579
 Maitan, M.A., 1244
 Major, C.D., 2721
 Makimura, H., 733
 Malavasi, F., 752, 985
 Malhotra, A., 1918
 Mallone, R., 752
 Mancham, V.P., 824, 2323
 Mandarino, L.J., 2572
 Maniatis, A.K., 1274
 Manteghetti, M., 1311
 Maor, G., 1691
 Marchesini, G., 1844
 Marchetti, P., 985, 1290
 Marette, A., 1901
 Markham, J., 1911
 Marlier, L.N.J.L., 1290
 Marounek, J., 972
 Marron, M.P., 1992
 Marrosu, M.G., 184
 Marsden, P.K., 2329
 Marshall, C.A., 353
 Marti, L., 2061
 Martin, C.C., 502
 Maruti, S., 681
 März, W., 776
 Masaki, T., 376, 385
 Masiello, P., 1970
 Masuzaki, H., 1093, 1440
 Matata, B.M., 2603
 Matsubara, H., 1472
 Matsuda, M., 2094
 Matsutani, A., 891, 1166
 Matsuzawa, Y., 1126, 1269, 2094
 Mattioli, P.L., 159
 Matzinger, O., 727
 McArdle, J.J., 2673
 McArthur, M.D., 1021
 McClure, K.D., 175
 McCoid, S.C., 593
 McCormack, J.G., 720, 1102
 McCullough, A.J., 1844
 McDaniel, M.L., 353
 McGarry, J.D., 123
 McIntosh, C.H.S., 1004
 McIntyre, S.S., 2001
 McKnight, G.S., 2555
 McQuaid, T.S., 1302
 Medow, M.S., 1414
 Meggs, L.G., 1918
 Meier, J.J., 2497
 Meijer, A.J., 2591
 Meile, M.-J., 1562
 Mejia, W., 1110
 Melchionda, N., 1844
 Melhem, M.F., 2114
 Melino, G., 1290
 Melloul, D., 1799
 Mensink, M., 2548
 Merlet-Bénichou, C., 1069
 Merriman, T.R., 184
 Mest, H.-J., 797
 Meyer, A. Parker, J., 675
 Meyer, J., 681
 Miao, D., 1274
 Michaeli, T., 348
 Michaud, S.é., 660
 Miele, C., 1244
 Miettinen, R., 1949
 Miles, P.D.G., 139
 Milla, C., 1336
 Miller, C.P., 1553
 Millevoi, C., 2619
 Minehira, K., 727
 Minicucci, F., 496
 Mirmira, R.G., 928
 Mitchell, G.A., 1970
 Mitchell, J.R.D., 248
 Mithieux, G., 740
 Miyagawa, J.-i., 1269
 Miyagawa, F., 227, 1440
 Mizuno, T.M., 733
 Mobbs, C.V., 733
 Moberg, E., 1604
 Modrick, L.M., 1580
 Mogensen, C.E., 630, 837
 Möhlig, M., 2641
 Mohlke, K.L., 886
 Möhrle, U., 2700
 Molano, R.D., 270, 1983
 Mølgaard, H., 837
 Molinari, N., 2164
 Møller, N., 96, 747, 2301
 Montano, S., 740
 Moore, A., 2231
 Moore, G.E., 199
 Moran, A., 1336
 Morcos, M., 2792
 Mordes, J.P., 972
 Morgan, D.A., 1119
 Morgan, D.G.A., 248
 Morgan, K., 2786
 Morgan, N.G., 340
 Mori, H., 891
 Morimoto, Y., 1206
 Morishita, R., 1472
 Moritz, J.T., 2040
 Moritz, W., 69, 521
 Moriwaki, M., 1269
 Moriyama, H., 1274
 Moriyama, Y., 1012
 Morris, R., 2431
 Mosthaf-Seedorf, L., 584
 Mott, D., 1828
 Mourtada, M., 340
 Mozzoli, M., 810
 Mulargia, A.P., 1200
 Müller, B., 521
 Munoz, K.N., 2472
 Muñoz, M.C., 131
 Murphy, G.J., 2148
 Murphy, K., 248
 Murphy, L.J., 32
 Musi, N., 921
 Mussoni, L., 1522
 Muurling, M., 2779
 Muzzin, P., 803
 Myhill, J., 123
 Mykkanen, L., 1949

N
 Nadal-Ginard, B., 1414, 2363
 Nadeau, A., 697
 Nadler, J.L., 1654
 Nagaretani, H., 2094
 Nagashima, H., 2100
 Nagy, A., 2100
 Nair, K.S., 96, 747, 947, 1336, 1351, 2652
 Nakagami, H., 1472
 Nakagawa, T., 2864
 Nakajima, H., 1269
 Nakamura, T., 2094
 Nakao, K., 227, 1093, 1440, 2296
 Nakatsuka, S., 1012
 Namba, M., 1269
 Nanjo, K., 891, 2864
 Nanmo, T., 1269
 Nano, R., 1290
 Napoli, R., 2709
 Narbonne, H., 462
 Nardone, N.A., 593
 Natale, S., 1844
 Natali, A., 1807
 Natarajan, R., 1654
 Nathanson, S.G., 1992
 Nauck, M.A., 776, 2497
 Nauck, M.S., 776
 Naumann, C.M., 291
 Nawrocki, A., 1056
 Nawroth, P.P., 2792
 Neal, D., 1872
 Neal, D.W., 367, 558, 2487
 Negri, S., 77
 Nelson, B.A., 2419
 Nerup, J., 184, 1056
 Neschen, S., 2309
 Nesher, R., 308
 Netticadan, T., 2133
 Neville, D.M., Jr., 1227

- Ng, E.H.C., 1004
 Nguyen, A., 39
 Nicaud, V., 1214
 Nicholls, A.J., 2047
 Nick, H., 515
 Nicklas, B.J., 2172
 Nielsen, P., 265
 Nielsen, S., 2301
 Nilsson, A., 2402
 Nishimura, H., 1093, 2296
 Nishimura, N., 1206
 Nishizawa, H., 2094
 Nisoli, E., 601
 Nitenberg, A., 1180
 Noël, G., 1531
 Nolte, L.A., 1397
 Nomura, A., 113
 Nørrelund, H., 96
 Notkins, A.L., 2406
 Nuutila, P., 1371
- O**
 Oakes, N.D., 1158
 Oberson, A., 77
 Obici, S., 2786
 O'Brien, P., 947
 O'Brien, R.E., 329
 O'Brien, R.M., 502
 Oeser, J.K., 502
 Oeth, P., 886
 Ofrecio, J., 1344
 Ogata, M., 694
 Ogawa, Y., 227, 1093, 1440, 2296
 Ogiwara, T., 573, 1472
 Oh, H., 867
 Ohba, M., 255
 Ohlsson, C., 1539
 Ohue, M., 113
 Oikonen, V., 1371
 Oka, Y., 891, 1166
 Okita, M., 1206
 Oksanen, A., 1371
 Okuya, S., 1166
 Olefsky, J., 2316
 Olefsky, J.M., 139, 1344
 Olesen, M., 1588
 Oliver, R., 1983
 Olsen, G.S., 584
 Olsson, U., 2126
 Olszewski, S., 2029
 Oluwale, O.O., 1546
 Oluwale, S.F., 1546
 Omer, A., 1698
 O'Neil, J.J., 1698
 Onishi, Y., 573
 Ono, H., 573
 Oostra, B.A., 637
 Opawumi, D., 1918
 Op 't Eijnde, B., 18
 O'Rahilly, S., 686, 2199
 Orban, T., 1735
 Orho-Melander, M., 675, 2402
 Oriente, F., 1244
 Ormoy, A., 2521
 Ørntoft, T., 909
 O'Rourke, L., 955
 Ortmeier, H.K., 1126
 Ortolan, E., 752
 Ortsäter, H., 2737
 Osei-Hyiaman, D., 2169
 Østenson, C.-G., 1449
- Osterhoff, M., 2641
 Ostrega, D.M., 2013
 Otani, A., 867
 Otani, K., 2013
 Otonkoski, T., 301
 Otsuka, M., 1012
 Ouchi, N., 2094
 Oxford, G.E., 2100
 Özçelikay, A.T., 455
- P**
 Pacini, G., 1539
 Pakkenberg, B., 1763
 Palacín, M., 2061
 Palm, F., 489
 Palmer, J.P., 1735
 Pamir, N., 1004
 Pampfer, S., 143
 Pan, C.-Y., 2013
 Pan, D., 622
 Panthier, J.-J., 2021
 Panzenböck, U., 1643
 Paramore, D.S., 1911
 Parent, R.J., 1698
 Park, K.S., 2837
 Park, Y., 895
 Parker, A., 681
 Paroni, R., 496
 Parving, H.-H., 1214
 Pastori, R.L., 1706, 1983
 Patel, M.S., 2053
 Patterson, B.W., 1402
 Pauza, M.E., 39
 Pavlovic, D., 551
 Peakman, M., 1749
 Pearson, S.L., 1102
 Peck, A.B., 2100
 Pedersen, N.L., 2410
 Pedersen, O., 12, 690
 Pedersen, S.B., 12
 Pederson, R.A., 1004
 Pederson, T.M., 24
 Pellet, L., 2040
 Peltoniemi, P., 1371
 Pennefather, P.S., 1302
 Pennock, C.A., 2047
 Péraldi-Roux, S., 1311
 Perego, C., 1290
 Perego, L., 1290
 Perfetti, R., 785
 Permutt, M.A., 322, 681
 Permet, A., 1618
 Perret, P., 1076
 Perretti, N., 1134
 Perrini, S., 2709
 Perrone, L., 2157
 Perry, G., 2792
 Perseghin, G., 277
 Perticone, F., 159
 Pérusse, L., 614, 697
 Peters, J.M., 2309
 Petersen, K.F., 1263
 Peterson, L.B., 2633
 Peterson-Wakeman, R., 166
 Pettiti, M., 1807
 Pfeiffer, A.F.H., 2641
 Phadke, S.A., 1482
 Phares, R.W., 436
 Philipson, L., 2472
 Phillips, B.G., 1119
 Phillips, M.S., 2633
 Phillips, S.L., 2114
- Piceni Sereni, L., 277
 Pignata, C., 483
 Pigon, J., 1449
 Pihlajamäki, J., 2396
 Pijl, H., 2779
 Pileggi, A., 270, 1706, 1983
 Pincus, S.M., 1778
 Pipeleers, D., 551
 Pipeleers, D.G., 1, 1771
 Pizzuti, A., 831, 1950
 Pociot, F., 184, 1056
 Podestà, F., 175
 Podolin, D.A., 1186
 Poehlman, E.T., 91
 Poirier, O., 1214
 Poitout, V., 315, 2481, 2809
 Pokras, F., 444
 Pollin, T.I., 91
 Polonsky, K., 322
 Polonsky, K.S., 150, 1828, 2013, 2472
 Pols, H.A.P., 637
 Polychronakos, C., 184
 Pontiroli, A.E., 1290
 Pontoglio, M., 2472
 Poot, M., 851
 Porat, M., 1425
 Pørksen, N., 776, 1778
 Portha, B., 1562
 Portocarrero, C.P., 1149
 Portolan, G., 2080
 Portugal, H., 462
 Post, C.M., 980
 Postic, C., 622
 Poulain, P., 2809
 Poulsen, P.L., 837
 Powers, W.J., 1911
 Pownall, H.J., 233
 Pozza, G., 277, 496, 2464
 Pralong, F.P., 2666
 Pratipanawatr, T., 2572
 Pratipanawatr, W., 2572
 Pratley, R.E., 1828
 Prentki, M., 803, 1970, 2237
 Previs, S.F., 1076
 Price, J.C., 2069
 Province, M.A., 614
 Pruschy, M., 2105
 Pugh, W., 2013
 Pugliese, A., 895
 Pulawa, L.K., 1064
 Pupilli, C., 985
 Purnell, J.Q., 1714
- Q**
 Quinn, A., 2459
 Quiñones-Galvan, A., 1807
- R**
 Raap, A., 797
 Rabbone, I., 483
 Rabinovitch, A., 710
 Rachdi, L., 2021
 Rafaeloff-Phail, R., 2822
 Rajas, F., 740
 Rajotte, R.V., 710
 Ramenghi, U., 483
 Ramlal, T., 1464
 Ranalli, M., 1290
 Rankinen, T., 697
 Rao, D.C., 614, 697
 Raoux, S., 1214
 Rask-Madsen, C., 2611
- Rattigan, S., 2659, 2682
 Ravussin, E., 707
 Reach, G., 2809
 Reddy, V., 2752
 Reed, L.J., 2329
 Reggio, H., 1311
 Reichart, D., 2316
 Reid, H., 1618
 Reijngoud, D.-J., 2591
 Reimann, F., 2253
 Reimann, M., 2641
 Reitman, M.L., 1440
 Renard, E., 2164
 Reneland, R., 690
 Renier, G., 660
 Rennich, J.S., 675, 681
 Resnick, H.E., 2384
 Reynisdottir, S., 1604
 Reynolds, T.H., 593
 Rhodes, C. J., 1791, 2029, 2181, 2237
 Ribeiro, M., 1706
 Ribes, G., 1311
 Rice, S.Q.J., 937
 Rice, T., 614
 Rich, S.S., 861
 Richard, A.-M., 56
 Richter, E.A., 18, 265
 Richter, W., 1976
 Ricordi, C., 270, 895, 1706, 1983
 Riesenberger, K., 1425
 Rigalleau, V., 727
 Rimm, E.B., 2390
 Riou, J.-P., 1134
 Rissanen, J., 1949
 Ristow, M., 2641
 Ritov, V.B., 1253
 Ritter, S., 2831
 Ritzel, R., 776
 Rizza, R.A., 565, 747, 1351
 Robertson, R.P., 47, 2481
 Robinson, K.A., 2419
 Roden, M., 392, 2309
 Roduit, R., 1970
 Roep, B.O., 1749
 Roepstorff, P., 1056
 Rohner-Jeanrenaud, F., 601
 Romeo, G., 175
 Romijn, J.A., 2585, 2591, 2779
 Rondinone, C.M., 24
 Rönnekaa, T., 1371
 Ronner, P., 291
 Rønningen, K.S., 184, 2879
 Rook, S.L., 444
 Rosenbaum, T., 1755
 Rosenthal, J.M., 1618
 Rosner, P.J., 2029
 Ross, L., 2858
 Ross, R., 2349
 Rossetti, L., 348, 1872, 2786
 Rossini, A.A., 972
 Rössner, S., 1604
 Rouault, C., 2809
 Rouiller, D.G., 1039
 Routh, V.H., 2673
 Roy, S., 614
 Roye, M., 1311
 Ruan, H., 233
 Rubens, M.B., 652
 Rudich, A., 1425
 Russell, R.R., III, 1076
 Russo, G., 667

- Rutter, G.A., 361
 Ryan, A.S., 2172
 Ryan, E.A., 710
 Ryan, L., 2842
 Ryder, J.W., 1149
- S**
 Saccomando, J., 2487
 Saccucci, F., 752
 Sachs, R., 1180
 Safai, B., 2363
 Sahai, A., 1482
 Saitta, A., 667
 Sakai, K., 32
 Sakata, T., 376, 385
 Sakoda, H., 573
 Salapatek, A. M. F., 1302
 Salmivirta, M., 2126
 Salt, I.P., 2148
 Salzmann, M.B., 2047
 Sampson, S.R., 255
 Sánchez, R.M., 1883
 Sánchez-Soto, M.C., 1755
 Sanders, N.M., 2831
 Sandqvist, M.M., 2344
 Sanke, T., 891, 2864
 Santagati, M.G., 1950
 Santopietro, S., 1244
 Santoro, N., 2157
 Sardella, A., 667
 Saris, W.H.M., 2548, 2870
 Sarvetnick, N., 2459
 Sasaoka, T., 1083, 1891
 Satchell, S.C., 2047
 Satin, L.S., 992, 2192
 Sato, Y., 1166
 Satoh, S., 1455
 Saudek, C.D., 2883
 Sauser, C., 77
 Savage, D.B., 2199
 Savola, K., 2625
 Sawcer, S., 184
 Sawtell, P.A., 2858
 Sblendido, M., 496
 Scarim, A.L., 283
 Schaart, G., 2870
 Schaeppi, M., 329
 Schalling, M., 2410
 Schally, A.V., 1110
 Scharfmann, R., 1219, 1571, 2021
 Schatz, M., 1612
 Scheek, L.M., 652
 Scheel, D., 928
 Schick, F., 2579
 Schiekofer, S., 2792
 Schlaeffer, F., 1425
 Schleicher, E., 2792
 Schmidova, K., 1714
 Schmidt, A.-M., 2792
 Schmiegell, W.H., 776, 2497
 Schmitz, O., 12, 776, 1778
 Schmitz-Peiffer, C., 2210
 Schneider, P., 727
 Schorderet, D.F., 77
 Schow, S.R., 824
 Schrauwen, P., 2870
 Schreyer, S.A., 2555
 Schröder, H.D., 1324
 Schuit, F., 361
 Schuit, F.C., 1
 Schulte, M., 776
- Schumann, W.C., 1872
 Schwaninger, M., 2792
 Schwarz, P.E.H., 694
 Schwenk, F.W., 565
 Schwenk, W.F., 1351
 Scirpoli, M., 2464
 Scott, L.J., 2842
 Scott, S., 1047
 Screenan, S., 2472
 Seal, L.J., 2540
 Seaquist, E.R., 2203
 Secchi, A., 277, 496, 2464
 See, W., 404
 Segal, D.G., 2199
 Segel, S.A., 1911
 Segu, V.B.G., 315
 Seino, S., 891
 Seino, Y., 891
 Sekihara, H., 1455
 Selvine, N., 573
 Senft, M., 462
 Sengenès, C., 2080
 Sengul, S., 2410
 Seppälä-Lindroos, A., 2337
 Sercarz, E., 2459
 Sergeev, P., 1683
 Serra, R., 601
 Serreze, D., 980, 2451
 Serreze, D.V., 763, 1992
 Serup, P., 1553
 Sesti, G., 1290
 Sewter, C.P., 2199
 Sha, L., 51
 Shafrir, E., 584
 Shah, P., 565, 1351
 Shapiro, A.M.J., 710
 Sharp, G.W.G., 329
 Shatford, J., 184
 She, J.-X., 2406
 Shen, S., 255
 Shepherd, P.R., 955
 Shepherd, R.M., 329
 Sherck, S.M., 2487
 Sherwood, S.J., 1495
 Shi, S., 824
 Shield, J.P., 184
 Shih, D.Q., 2472
 Shike, T., 1943
 Shimajiri, Y., 2864
 Shimizu, T., 2438
 Shimomura, I., 2094
 Shin, P., 83
 Shintani, M., 227, 1093, 1440, 2296
 Shiota, M., 367, 622, 2487
 Shirai, T., 1943
 Shojima, N., 573
 Short, K.R., 2652
 Shuldiner, A.R., 91, 2172
 Shulman, G.L., 1076, 1263
 Silveira, P., 1992
 Silverstein, J., 733
 Simmons, A., 1618
 Simmons, R.A., 2279
 Simoneau, J.-A., 195
 Singh, B., 2451, 2459
 Singh, L.P., 2355
 Sinopoli, F., 159
 Sironi, A.M., 1807
 Sironi, L., 1522
 Sivitz, W.I., 1119
 Sizyakov, G., 1627
- Sjögren, K., 1539
 Skau, M., 1763
 Skelly, R.H., 1791
 Skorecki, K.L., 1691
 Slosberg, E.D., 1813, 2287
 Small, C.J., 248, 248, 2540
 Smith, G., 2641
 Smith, M., 2792
 Smith, S.B., 928
 Smith, V., 2763
 Smyth, C.A., 1227
 Snieder, H., 2858
 Socci, C., 277
 Sodhi, C.P., 1482
 Söhnlein, P., 1976
 Somwar, R., 1464
 Song, F., 2053
 Song, S., 515
 Song, X.M., 1149, 2770
 Song, Z., 2673
 Spampinato, D., 831, 1950
 Spector, T.D., 2858
 Spevak, W.R., 824
 Spiller, D., 2431
 Spinass, G.A., 69, 1683, 2105
 Spranger, J., 2641
 Spravchikov, N., 1627
 Squadrito, F., 667
 Squadrito, G., 667
 Sreenan, S.K., 2013
 Srinivasan, M., 2053
 St. Denny, L., 1813
 Stadelmaier, B.T., 502
 Staehr, P., 1324, 1363
 Staels, B., 2809
 Stafford, D., 322
 Stampfer, M.J., 2390
 Stangé, G., 551
 Stanier, P., 199
 Stanley, C.A., 322
 Stanley, S.A., 248, 2540
 Stavrou, S., 1227
 Steenkiste, A.R., 1857
 Stefan, N., 882, 1143, 2161
 Stefanelli, C., 1580
 Stefanoni, N., 727
 Steiner, D.F., 534
 Stene, L.C., 2879
 Stephan, Z., 2287
 Stern, D.M., 2792
 Stevenson, R.W., 593
 Stewart, A.F., 2752
 Stickland, M.H., 1505, 2646
 Stingl, H., 392
 Stoffel, M., 2472
 Stoffers, D.A., 1553
 St-Onge, J., 195
 Storgaard, H., 2770
 Straub, S.G., 329
 Straume, M., 2001
 Strotmeyer, E.S., 1857
 Stumvoll, M., 876, 882, 1143, 2161, 2579
 Sturgis, L., 1495
 Suarez, B.K., 681
 Suckling, J., 1618
 Sugden, M.C., 2729
 Sugihara, H., 2438
 Sun, Y., 1047
 Surico, N., 985
 Sutherland, C., 937
 Sutherland, D.E.R., 47
- Suzuki, L.A., 851
 Suzuma, I., 444
 Suzuma, K., 444
 Svensson, H., 2225
 Svensson, L., 1539
 Svenstrup, K., 1553
 Svetlanov, A., 980
 Svitek, C.A., 502
 Sweeney, G., 1464
 Swenberger, J.R., 1389
 Szczepaniak, L.S., 123
 Szurszewski, J.H., 51
 Szwegold, B.S., 2139
- T**
 Taheri, S., 2540
 Tai, T.-Y., 2598
 Takagi, H., 867
 Takahashi, M., 2094
 Takala, T.O., 1371
 Takane, K.K., 2752
 Takano, A., 1083, 1891
 Takasu, N., 2864
 Takata, Y., 1083
 Takaya, K., 227
 Takeda, J., 891
 Tamemoto, H., 1455
 Tamura, H., 2438
 Tamura, S., 1269
 Tanabe, K., 1166
 Tanaka, Y., 2481
 Tang, J., 1938
 Tang, S., 83
 Tang-Christensen, M., 2530
 Taniyama, Y., 1472
 Tanizawa, Y., 1166
 Tao, Q., 992
 Tappy, L., 727
 Tarnow, L., 1214
 Tassi, V., 1950
 Tataranni, P.A., 707, 901
 Tay, A., 455
 Taylor, R., 1102
 Tchernof, A., 91
 Teague, J., 992
 Teigeler, A., 882
 Templeton, L.J., 2279
 Temsah, R.M., 2133
 Tennenbaum, T., 255, 1627
 Terauchi, Y., 1455
 ter Harsel, A., 2591
 Terruzzi, I., 277
 Teruel, T., 2563
 Testar, X., 2061
 Testers, L., 637
 Tetzloff, G.G., 1330
 Thalén, P.G., 1158
 Thearle, M., 2268
 Theofilopoulos, A.N., 184
 Thomas, F.T., 1227
 Thomas, H.E., 2744
 Thomas, J., 681
 Thomas, J.D., 675
 Thomas, J.M., 1227
 Thomas, M.J., 1021
 Thomas, M.K., 521
 Thorell, A., 921
 Thorens, B., 1282, 1720
 Thörne, A., 1604
 Thornton, P.S., 322, 2763
 Tian, Y., 2505
 Tilton, R.G., 1495

- Timsit, J., 1211
 Tirosh, A., 1425
 Tisch, R., 2459
 Tkac, I., 2203
 Toavs, D.K., 824
 Tobe, K., 1455
 Todd, J.A., 184, 1200, 2633
 Toffolo, G., 150
 Tomassetti, S., 1844
 Tomino, Y., 1943
 Tonello, C., 601
 Topp, B.G., 1021
 Törnelli, J., 1539
 Tornheim, K., 56
 Torp-Pedersen, C., 2611
 Torre, V., 667
 Toschi, E., 1807
 Tourrel, C., 1562
 Toyosawa, K., 113
 Tracy, R.P., 2384
 Tree, T.I., 1749
 Tremblay, F., 1901
 Tremoli, E., 1522
 Trencia, A., 1244
 Tribillac, F., 1311
 Trischitta, V., 831, 1950
 Tritschler, H., 2792
 Tschöp, M., 707
 Tse, C.A., 1821
 Tsuji, Y., 1455
 Tsushima, R.G., 1302
 Tu, A.-Y., 1851
 Tucker, M.Z., 1389
 Tuomilehto, J., 184, 886
 Tuomilehto-Wolf, E., 184
 Turcotte, L.P., 1389
 Turner, A.N., 91
 Tyrberg, B., 301
 Tzeng, T.-F., 2815
 Tzukerman, M., 1691
- U**
 Ueno, E., 1083, 1891
 Ueno, N., 1206
 Uffelman, K.D., 1402
 Underwood, S.R., 652
 Undlien, D.E., 184
 Uno, S., 1269
 Uno, T., 1083, 1891
 Urna, G., 667
 Ursø, B., 18
 Usellini, L., 1290
 Ustinov, J., 301
 Usui, I., 1083, 1891
- V**
 Vaag, A., 2770
 Vaessen, N., 637
 Vähäsalo, P., 2625
 Valensi, P., 1180
 Valle, T.T., 886
 Vallejo, M., 521
 van Baak, M.A., 2548
 Van Cauwenberge, A., 143
 Vanderheyden, I., 143
 Van Der Smitten, P., 143
 van Duijn, C.M., 637
 van Ender, P., 1749
- Van Gent, T., 652
 van Heek, M., 1330
 Van Huyen, J.P.D., 1069
 Vanounou, S., 1425
 van Rossum, E.F.C., 2172
 Van Schaftingen, E., 1531
 Van Tol, A., 652
 Vasavada, R.C., 2752
 Vaultont, S., 1515
 Vaxillaire, M., 1219
 Vázquez, M., 1883
 Vega, N., 1134
 Vehkavaara, S., 2337
 Veldhuis, J.D., 1778, 2001
 Vella, A., 565, 1351
 Ventura, G., 159
 Venturini, M., 496
 Verchere, C.B., 534
 Vestbo, E., 630
 Vettor, R., 601
 Violettes, B., 462
 Vidal, H., 1134
 Vidal, J., 2514
 Vidal-Puig, A., 2199
 Videen, T.O., 1911
 Vigliotta, G., 1244
 Vigneri, R., 831, 1950
 Vigouroux, C., 1378
 Villar, H.O., 824
 Vilsbøll, T., 609
 Viollet, B., 1515
 Vionnet, N., 1214
 Virkamäki, A., 2337
 Vizzardelli, C., 270, 1983
 Vlassara, H., 1214
 Vogel, M., 1976
 Volk, A., 882
 von Herrath, M., 39, 2459
 von Herrath, M.G., 2700
 Voshol, P.J., 2585, 2779
 Voss, M.C., 1056
 Vranic, M., 1402
- W**
 Wagenknecht, L.E., 861
 Wagenmakers, A.J.M., 2548
 Wagner, L., 2309
 Waguri, M., 1269
 Wahl, H.G., 876
 Wakabayashi, I., 2438
 Wakeling, E.L., 199
 Waldhäusl, W., 392, 2309
 Walker, E.A., 2883
 Walker, J., 2858
 Wallenius, K., 1539
 Wallis, M.G., 2659
 Wang, F., 2514
 Wang, H., 1949
 Wang, J., 63, 515, 534, 928, 2786
 Wang, R., 166
 Wang, S.P., 1970
 Wang, Y., 1821
 Wang, Z., 166
 Wareham, N.J., 686
 Warnock, G.L., 710
 Warram, J.H., 204, 2842
 Warwar, N., 308
 Wasserfall, C., 515
- Wasson, J.C., 681
 Watada, H., 928
 Watanabe, R.M., 886
 Watanabe, T., 376, 385
 Watkins, S., 817
 Watson, D.G., 411
 Weber, M., 1683
 Wegmann, D., 1274, 2459
 Wegmann, D.R., 1729
 Weigle, B., 2792
 Weigle, D.S., 1714
 Weir, G.C., 1698, 2709
 Weiser, P., 972
 Weisnagel, S.J., 697
 Weiss, R., 1193
 Weisser, M., 2161
 Weissleder, R., 2231
 Weksler-Zangen, S., 2521
 Welsh, E.M., 2001
 Welsh, K., 1200
 Wen, L., 2459
 Wertheimer, E., 255, 1627
 Westerlund, J., 51, 1785
 Weyer, C., 707, 1828
 Whalen, B.J., 972
 Wheeler, M.B., 1302
 White, M., 2431
 White, M.F., 2164
 Whiteside, C.I., 2376
 Wick, M.M., 824
 Wicker, L.S., 2633
 Wicksteed, B., 1791
 Wiegman, C.H., 2591
 Willett, W.C., 2390
 Williams, G., 105, 2431
 Williams, K.V., 2069
 Williams, P.E., 2487
 Williams, S.C.R., 1618
 Wilson, C., 1828
 Wilson, M.C., 361
 Wilson, S., 105
 Winkler, C., 1211
 Wintersperger, A., 1643
 Winzell, M.S., 2225
 Wisse, B.E., 1714
 Witteman, J.C.M., 637
 Wojtazewski, J.F.P., 265
 Wolf, B.A., 2721
 Wolfe, T., 39, 2700
 Wollheim, C.B., 1039, 1311
 Wordsworth, P., 184
 Wortel, J., 1237
 Wren, A.M., 2540
 Wright, C., 785
 Wu, L., 166
 Wu, Y., 1110
- X**
 Xie, J., 2406
 Xu, A., 1821
 Xu, F., 1302
 Xu, G., 353
 Xu, J., 534
- Y**
 Yagil, C., 2521
 Yagil, Y., 2521
 Yáguez, L., 1618
- Yakar, S., 1110
 Yamada, H., 1012
 Yamada, N., 891
 Yamagata, K., 891, 1269
 Yamagishi, S.-i., 1491
 Yamamoto, A., 1012
 Yamamoto, K., 1269, 1472
 Yamamoto, Y., 1093
 Yaney, G.C., 56
 Yang, C., 2598
 Yang, D., 2001
 Yang, X.-J., 733
 Yang, X.M., 348
 Yang, Y., 2691
 Yaniv, M., 2472
 Yarasheski, K.E., 1397
 Yasuda, K., 891
 Yaworsky, K., 1464
 Ye, J., 1821
 Ye, J.-M., 411
 Yeaman, S.J., 720, 955, 1102
 Yee, A.J., 1389
 Yeh, C.-H., 1495
 Yki-Järvinen, H., 1371, 2337
 Yokoi, N., 891
 Yonemitsu, S., 1093, 2296
 Yoon, J.-W., 2691
 Yorek, M.A., 1927
 Yoshimasa, Y., 1440
 Yoshimatsu, H., 376, 385
 Yoshimura, S.-i., 1472
 Yoshimura, Y., 1992
 Youd, J.M., 2659
 Youn, J.H., 418
 Young, L.H., 1076
 Youngren, J.F., 2323
 Yu, C., 1263
 Yu, H., 2169
 Yu, J.G., 1344
 Yu, L., 1274, 1735
 Yu, M., 1149
- Z**
 Zagury, J.-F., 1211
 Zaitsev, S.V., 797
 Zangen, D.H., 2521
 Zechner, R., 1643, 2585
 Zekzer, D., 2459
 Zeller, M., 895
 Zelles, T., 2100
 Zennaro, C., 2619
 Zethelius, B., 690
 Zhang, B.B., 2323
 Zhang, M., 2192
 Zhang, X.-N., 1495
 Zhao, C., 361
 Zhiming, Z., 2169
 Zhiyin, R., 2169
 Zhou, Y.-P., 2013
 Zierath, J.R., 1149, 2770
 Zimmerman, E.F., 1193
 Zimmermann, R., 1643
 Zitoun, C., 740
 Ziv, E., 584
 Zorzano, A., 2061
 Zulewski, H., 521

